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Since the discovery of gp96 in the 1980’s as a “tumor rejection antigen,” Heat Shock Proteins 
(HSPs) have received attention from immunologists for their ability to prime immune responses. 
Originally known for their important intracellular roles as chaperones to newly synthesized, 
misfolded, and/or recently degraded proteins, it is now understood that HSPs released into the 
extracellular environment can also initiate immune responses. Shown both in vitro and in vivo, 
HSPs act on antigen presenting cells (APC) to 1) deliver antigenic peptides for presentation by 
both MHC class I and class II molecules and 2) activate APC to increase expression of co-
stimulatory molecules. Both of these activities contribute to productive T cell responses, which 
has led to current trials using HSP-peptide complexes as cancer vaccines. However, the cell 
populations responsible for monitoring exogenous HSPs and priming resulting immune 
responses have yet to be fully characterized. This study identifies the cells that incorporate HSPs 
in vivo, following either vaccination or release by tumors, and analyzes the immune response 
generated by these cells. A CD11c+CD11b+CD4+ dendritic cell population selectively takes up 
HSPs, coincident with higher expression of the HSP receptor CD91 on these cells. We also show 
the dependence on CD91 of HSP-mediated immune responses. Increased knowledge of the 
process by which HSPs shape immune responses will contribute to the understanding of HSP-
mediated immunity as well as assist in optimizing current tumor-vaccine strategies.  
Analysis of cellular sentinels for extracellular Heat Shock Protein-peptide complexes 
Michelle N. Messmer, PhD 
University of Pittsburgh, 2013
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1.0  PROJECT AIMS 
Heat Shock Proteins (HSPs) have been described as early precursors of innate immunity, acting 
as danger signals in the extracellular environment. They are also involved in adaptive immunity, 
delivering peptides for efficient processing and presentation on MHC. HSPs such as gp96 
isolated from tumor cells elicit tumor peptide-specific immunity in mice. For this reason, the use 
of HSPs as tumor vaccines is currently under clinical investigation.  
Though it is clear that gp96 provokes immune responses, the cellular targets of gp96 in 
vivo are not known.  Exogenously added gp96 or gp96 released into the extracellular 
environment, due to membrane damage or active secretory mechanisms, may be taken up by 
cells expressing the HSP receptor CD91. Importantly, gp96 may be taken up by peripheral 
dendritic cells for transport to lymph nodes or it may passively drain through the lymphatics to 
be taken up by lymph node resident cells to prime T-cell responses. Subtypes that selectively 
take up gp96 may determine the type of response produced. This study identifies cells that 
incorporate HSPs in vivo, following either vaccination or release by tumors, and analyzes 
the immune response generated by these cells. Expression of the HSP receptor CD91 is 
assessed for each subset. The ability of these cells to prime immune responses is also analyzed. 
These studies improve our understanding of the immunologic role of HSPs as well as provide 
insight for enhanced cancer treatment strategies. 
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1.1 AIM 1: DETERMINE THE CELLULAR SENTINELS OF HSPS IN A VACCINE 
SETTING 
Fluorescent labeling of gp96 allowed for tracking of this HSP to draining lymph nodes following 
vaccination. Cells that took up fluorescent protein were then phenotyped by flow cytometry and 
immunofluorescent microscopy. Sorted cell populations were analyzed for their ability to 
generate immune responses. This aim identifies CD11c+CD11b+ cells in the subcapsular region 
of the lymph node as the major endocytic cells for gp96, both due to their expression of CD91 
and their prime localization.  
 
Figure 1-1. Model for HSP trafficking to LN for generation of immune responses. 
There are multiple potential routes for gp96 trafficking. Following intradermal injection, gp96 may be taken up by 
CD91 expressing cells at the site of injection and be retained there (1). (2) However, since gp96 is a soluble 
molecule, gp96 may drain through the lymphatics to LNs where it may interact with LN resident cells to stimulate 
immune responses. Alternatively, gp96 may be internalized by skin resident dendritic cells that migrate to LN 
following activation (3). These migratory cells may be responsible for presenting gp96-chaperoned antigen to 
generate immune responses themselves or they may transfer antigen to LN resident cells for priming (4).  
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1.2 AIM 2: EXAMINE IMMUNE RESPONSES TO HSPS RELEASED BY TUMORS 
Tumor cells expressing EGFP-tagged gp96 were generated and used to track this HSP to tumor-
draining lymph nodes. This effect was blocked by introduction of a competitive endogenous 
inhibitor of the HSP receptor CD91. Additionally, abrogation of CD91 expression reduced 
immunogenicity of tumor cells.  This aim demonstrates a dependence on HSPs and CD91 for 
induction of tumor-specific immunity.  
 
Figure 1-2. Model for HSP release from tumor to generate immune responses. 
Tumor-derived extracellular gp96 may drain to LN along routes akin to those proposed in Figure 1-1. A: (1) Non-
migratory CD91+ cells within or surrounding the tumor may endocytose gp96 and retain it at that location. Excess 
gp96 may passively drain via the lymphatics to LN resident cells to generate anti-tumor immune responses (2). 
Migratory skin resident dendritic cells may also carry gp96 to draining LNs (3) where they may directly promote 
immune responses or undergo antigen transfer with a LN resident subset (4). An additional mechanism of tumor-
derived gp96EGFP delivery to the lymph nodes may be in the form of drainage of apoptotic tumor cell fragments or 
exosomes containing HSPs (5). B: Studies have suggested at least two mechanisms for tumor release of HSPs into 
the extracellular environment: either through tumor cell necrosis or via active secretion.    
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1.3 AIM 3: IDENTIFY ANTIGEN-PROCESSING PATHWAYS FOLLOWING 
HSP:CD91 INTERACTION 
Bone marrow derived dendritic cells are used to analyze the endocytosis of HSP:peptide 
complexes. Intracellular localization shows peptide translocation into the cytosol and a lack of 
interaction between gp96 containing endosomes and the lysosomal compartment. Additionally, 
levels of the HSP receptor CD91 are examined on these cells following activation with LPS. This 
aim defines important intracellular processes that give rise to HSP-mediated immunity.  
 
Figure 1-3. Model for the cellular effects of HSP:CD91 interaction. 
A number of downstream effects of HSP:CD91 interaction remain to be elucidated. (1) HSP:peptide complexes 
engage with the surface receptor CD91 and are then internalized. (2) Endocytosis of this complex has previously 
been visualized but the fate of gp96 or the chaperoned peptide, including their localization with major cellular 
organelles, is still unclear. (3) Extended length peptides chaperoned by gp96 can ultimately be presented by both 
MHC class I and MHC class II, despite theoretically separate processing pathways. (4) In addition to delivery of 
peptides for processing, HSP:CD91 interaction stimulates increased expression of maturation markers such as MHC 
class II on APC. (5) Stimulation of TLRs with LPS also matures APC to increase expression of MHC class II. The 
effects of APC maturation on CD91 expression are unknown, but we can use LPS signaling as a non-specific 
stimulator of DC to investigate this.  
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2.0  BACKGROUND  
Heat shock proteins (HSPs) are ubiquitously expressed in eukaryotic and prokaryotic cells. They 
play pivotal roles in protein folding and cell cycle regulation, and several members show high 
evolutionary conservation [1,2].  Uniquely, a subset of these proteins have been observed to 
generate highly effective and specific immune responses, earning them the title “immunogenic.” 
This chapter covers what is known regarding the major immunogenic HSPs and mechanisms of 
HSP-mediated immune responses, including direct effects of HSPs on various cells of the 
immune system and dependence on the HSP receptor CD91. It will establish roles for HSPs in 
several aspects of immunity. Finally, data from recent clinical trials of HSP-based vaccines will 
be reviewed to highlight the need for expanded understanding of the cells acting to generate 
HSP-mediated immunity.  
2.1 DISCOVERY OF THE IMMUNOGENIC HSPS 
For over three decades, scientists have appreciated that heat shock proteins generate immune 
responses. This section details the original discoveries defining immunogenic HSPs as a special 
class of proteins.  
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2.1.1  Identification of “Tumor Rejection Antigen” gp96, a prototypic immunogenic HSP 
The middle of the 20th century witnessed great debate over whether the immune system was 
capable of recognizing and defending against tumor cells. Some believed tumors did not contain 
the requisite antigens to stimulate immune cells.  However, a series of elegant experiments in the 
1940’s and ‘50’s showed that tumors, particularly chemically induced sarcomas, do possess 
unique antigens that can produce anti-tumor immunity [3-6].  A slew of “tumor rejection 
antigens” were identified in the following decades, often in the form of mutated, over-expressed, 
or aberrantly expressed normal proteins. 
TRAs seemed to be highly unique, such that inoculation with one tumor rarely protects 
against challenge with even closely related tumors. To efficiently isolate new TRAs for study, 
researchers purified TRAs using 
column chromatography, monitoring 
the antigenicity of each fraction. In 
this way, Srivastava et al. discovered 
an apparently common TRA isolated 
from two distinct 
methylcholanthrene induced 
sarcomas [7]. Despite having 
undergone identical isolation 
procedures, this 96 kDa TRA retains 
specificity for the tumor of origin. 
TRA isolated from Meth A was 
 
Figure 2-1. “Tumor Rejection Antigen” promotes tumor-specific 
immunity. 
Isolation of a 96 kDa protein from two distinct methylcholanthrene-
induced sarcoma cell lines induces tumor specific protection in 
vaccinated mice. Original publication: Figure 4 [7].  Copyright 1986 
Srivastava. 
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protective against Meth A fibrosarcoma but not protective against the closely related tumor, 
CMS5, and vice versa (Figure 2-1). This tumor rejection antigen was called gp96. Structural and 
biochemical similarities between the TRAs reported in this first paper, combined with intensive 
comparisons between various gp96 isolates as well as genetic mapping of the gp96 gene from 
normal and tumor tissue as well as between mouse and human, failed to uncover the source of 
tumor specificity [8-14].  However, these studies did identify gp96 as a ubiquitously expressed 
stress-induced heat shock protein.  
2.1.2 Additional immunogenic HSPs 
In addition to gp96, other immunogenic HSPs, as defined by their ability to elicit tumor/peptide 
specific immune responses, include the following structurally diverse proteins: hsp90 [15,16], 
hsp70 [16-18], calreticulin [19], hsp110 [20,21] and grp170 [20]. The major receptor for four of 
these HSPs (hsp90, hsp70, gp96, and calreticulin) has been confirmed to be CD91 [22,23], 
discussed at length in the section “Discovery of the HSP Receptor CD91” (Chapter 2.3, page 13). 
Other potential receptors for immunogenic HSPs will not be discussed at length, but will be 
mentioned where appropriate.  
Even for HSPs sharing the same receptor, functional differences have been reported. A 
direct comparison of the immunogenicities of  hsp90, hsp70 and gp96 within a single tumor 
vaccine model found molar equivalents of hsp70 and gp96 outperformed hsp90 in tumor 
rejection assays [16]. At the time, this was attributed to potential differences in peptide 
chaperoning ability (discussed below), but we have also shown that treatment with hsp70, 
calreticulin or gp96 elicits different cytokine profiles both in vitro and in vivo, independent of 
specific peptide binding [24]. These functional differences remain an intriguing area of research.  
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2.1.3 The specific nature of HSP immunogenicity 
A number of the immunogenic HSPs were implicated as TRAs around the time gp96 was 
identified [15,17,21], coincident with observations that HSPs function by binding peptides to 
assist in protein folding [25]. Since no intrinsic differences in tumor vs. normal HSPs could be 
found, this led to the theory that the peptide-binding ability of HSPs was also the source of their 
antigenicity [11]. It was soon shown that gp96 has measurable ATPase activity, akin to other 
heat shock proteins, and peptides can be stripped from the purified protein [26]. These peptides 
associate with HSPs such as gp96 within the cell and are not contaminates from the purification 
process [27]. Stripping peptides from HSPs abrogates tumor-specific immunity [17]. Further, it 
was found that peptides can be exogenously complexed to hsp70 and gp96, albeit under different 
experimental conditions, and that it is only after direct association, rather than simply being 
mixed, that these HSPs enhance peptide specific immunity [28].  
As reviewed elsewhere [29], multiple antigenic systems have been used to test HSP-
mediated immunity. Defined epitopes from bacteria, viruses, tumors, and model antigens have 
been shown to associate with HSPs (Table 2-1). In comparison to the relatively strict peptide-
binding requirements for MHC molecules, peptides stripped from HSPs are a heterogeneous pool 
with limited length restrictions and loose sequence requirements [26,30-35]. Comparing the 
peptides isolated from HSP70, HSP90, and gp96 identified differences in the endogenous peptide 
repertoire chaperoned by these HSPs [36]. This may be due to differences in cellular localization 
(hsp90, hsp70, hsp110 are primarily located in the cytosol whereas gp96, calreticulin, and 
grp170 are usually retained in the endoplasmic reticulum), or they may be shaped by a natural 
directional pathway for peptide processing that delineates sequential interactions with each HSP 
family member [37,38]. Given the structural diversity of the immunogenic HSPs, differences in 
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the identified peptide binding sites may also account for their peptide selectivity [39-41]. The 
full crystal structure for gp96 has been solved [42], and it is believed that immuno-relevant 
peptide binding occurs on the N-terminal domain [30,43-46], although the chaperoning functions 
of gp96 depend on the C-terminal domain [43,46-48].   
Table 2-1. Examples of peptide epitopes associated with immunogenic HSPs 
CTL epitope MHC I Restriction Reference 
PRL1a Ld Ishii et al. 1999  [36] 
MART1, gp100 melanoma ags A2 Castelli et al. 2001 [49] 
HPV16 E7 Ag Db, A2 Ren et al. 2010 [50], Ding et 
al. 2013 [51] 
Pokemon  Yuan et al. 2012[52] 
RCC Ags  [35] 
Vesicular stomatitis virus Kb Suto & Srivastava 1995 [53], 
Nieland et al. 1996 [54] 
Simian virus 40 Db, Kb Blachere et al. 1993 [55], 
1997 [28] 
Influenza Kb Blachere et al. 1997 [28],  
Heikema et al. 1997 [56] 
Herpes simplex virus-2 d, A2 Navaratnam et al. 2001 [57], 
Mo et al. 2011 [58] 
Hepatitis B  Meng et al. 2001 [59] 
M. tuberculosis d Zugel et al. 2001 [60] 
Listeria d Sponaas et al. 2001 [61] 
Ovalbumin Kb Breloer et al.  1998  [62],  
Blachere et al.  1997 [28],  
Kropp et al. 2010 [37] 
Beta-galactosidase Ld Arnold et al. 1995 [63], 1997 
[64], Binder et al. 2007 [65] 
Minor Histocompatibility Antigens Kb, Kd Arnold et al. 1995 [63], 1997 
[64] 
This table was adapted from the review by Binder in 2006 [29]. Examples include peptides derived from human 
cancers, viral antigens, bacterial antigens, model antigens, and minor histocompatibility antigens. 
 
Thus, immunogenic HSPs derive their tumor specific antigenicity from the peptides they 
are endogenously or exogenously associated with, but this does not explain the enhanced 
 10 
immune responses observed for HSP-peptide complexes compared to non-HSP associated 
antigens. The targeting of HSPs to professional APCs combined with stimulation of innate 
effects will be explored in detail in the next two sections, 2.2 Factors associated with HSP-
mediated immunity and 2.3 Discovery of the HSP Receptor CD91.  
2.2 FACTORS ASSOCIATED WITH HSP-MEDIATED IMMUNITY 
This section details the cellular players in HSP-mediated immunity as well as the innate effects 
HSPs have on cells of the immune system. 
2.2.1 Cellular requirements for HSP-
mediated immunity 
Upon observing the effective anti-tumor 
immune responses elicited by 
immunogenic HSPs, researchers began to 
dissect the cellular mediators of this 
response. Treating mice with carrageenan, 
a polyanionic polysacharride ligand for a 
number of scavenger receptors, to ablate 
phagocytic cells during the priming phase 
diminished anti-tumor protection in 
response to purified gp96 but not whole 
 
Figure 2-2. Requirement for phagocytic cells for HSP-
mediated immunity. 
Vaccination of mice with either whole cell lysate of Meth A 
or gp96 purified from Meth A cells was protective against 
challenge with Meth A (top row). Treatment of mice with 
carrageenan to ablate phagocytic cells abrogated gp96-
mediated protection, but not lysate-mediated protection, 
demonstrating a differential requirement for APCs.   
Original publication: [66], Figure 5. Copyright (1994) 
National Academy of Sciences, U.S.A.  
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cell lysates (Figure 2-2, [66]). Additionally, it was found that immune responses to purified gp96 
were highly dependent on CD8+ cells during priming, such that antibody depletion of CD8+ cells 
at the time of vaccination ablated the observed protection [66]. These cells, however, were 
dispensable during the priming phase following whole cell vaccination. It was hypothesized that 
the phagocytic cells played a major role as acceptors of HSP-peptide complexes for cross-
presentation of antigen on MHC class I to stimulate strong CTL responses [38]. The mechanism 
for this targeted up-take for effective processing and presentation of peptide will be discussed in 
Section 2.3. However, we also know that, beyond peptide presentation, additional support from 
mature APCs is required for effective immune responses [67]. Cells required during the effector 
phase of gp96-mediated immunity include CD4+, CD8+ and NK cells [18,66]. Innate effects of 
HSPs include stimulating the production of cytokines and co-stimulatory molecules by APC to 
shape these downstream effector phase responses.  
2.2.2 Innate effects of HSPs 
In addition to delivering peptides for efficient processing and presentation, immunogenic HSPs 
stimulate non-specific, innate immune responses. Treatment of APCs in vitro with immunogenic 
HSPs has a number of effects, as summarized in Table 2-2 (adapted from [23]). This includes 
translocation of NF-κB, stimulation of cytokine and chemokine production (ex. TNFα, IL-12p40, 
IL-1β, IL-6, RANTES), up-regulation of activation and co-stimulatory markers (ex. MHC class 
II, CD80, CD86, CD83, CD40), as well as production of nitric oxide. The observed effects are 
independent of any bound peptide and vary depending on the target cell as well as the identity of 
the HSP used.  
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Table 2-2. Selected reports showing activation of APCs by HSPs 
Type of HSPs Targeted cells Markers of Activation Inflammatory 
mediators  
Year Ref.  
gp96, HSP70, 
HSP90 
DC NF-κB translocation,  
↑MHC II and CD86 
TNF-α, IL-12, IL-1β 2000 [68] 
gp96, HSP70, 
CRT 
RAW264.7, 
PEC 
NF-κB translocation TNF-α, IL-1β, IL-6, 
etc.  
CXCL10 (IP-10), 
CXCL11 (IP-9) 
2011 [24] 
Human HSP70, 
gp96 
DC ↑HLA-DR, CD40, CD86, 
CD83, DC-LAMP 
 2001 [69] 
Human & 
mouse, gp96 & 
HSP70 
macs,  
immature DC 
 NO 2002 [70] 
gp96 human DC ↑ MHC II,CD86 TNF-α, IL-12 2000 [71] 
gp96 CD11c+ cell ↑MHC II, CD80, CD86, 
DC migration 
 2000 [72] 
gp96 PMN, mon  IL-8 2003 [73] 
Human gp96 BMDC NF-κB translocation,  
↑CD86 
IL-12 2002 [74] 
Human gp96 macs  TNF-α, IL-8 2009 [75] 
HSP70 Splenocytes  TNF-α,IL-1β, IL-6 2000 [76] 
HSP70 BMDC  TNF-α, IL-12, IL-1β, 
IL-6 
2000 [77] 
HSP70 Tumor cells, 
DC 
NF-κB translocation, ↑ 
CD80, CD86, CD40, 
MHC II 
CXCL10 2009 [78] 
Human HSP70 mon NF-κB translocation TNF-α,IL-1β, IL-6 2000 [79] 
Human HSP70 DC  IL-12 2002 [80] 
Human 
rHSP70 
DC ↑CD40, CD86,CD83  2001 [81] 
Human 
rHSP70 
DC  IL-12p40 2003 [82] 
Mtb HSP70 THP1, KG1 
cells, DC 
 RANTES 2001 [83] 
Mycobacteria 
rHSP70 
Human DC ↑CD83, CCR7, CD86, 
CD80, HLA-DR 
RANTES, IL-12, TNF-
α Nitric oxide 
2002 [84] 
Rat HSP72 Splenocytes, 
macs 
 NO, TNF-α, IL-1β, IL-
6 
2003 [85] 
Human 
Hsp70L1 
DC  TNF-α, IL-12p70, IL-
1β, IP-10, MIP-1α, 
MIP-1β, RANTES 
2004 [86] 
Mycobacteria/ 
human HSP60, 
HSP70 
PEC  IL-12 1996 [87] 
This table is adapted from Table 2 of our review of HSPs and immune responses [23]. Species is mouse unless 
otherwise indicated. Cell lines are italicized. Abbreviations: r, recombinant; CRT, calreticulin; mon., monocytes; 
PEC, peritoneal exudate cells/macrophages; macs. macrophages; DC, dendritic cell; BM, bone marrow derived; LC, 
Langerhaans cells; PMN, polymorphonuclear leukocytes; NO, nitric oxide. 
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The inflammatory responses produced by APCs treated with HSPs are expected to 
support development of strong CTL-mediated immunity. However, HSP interactions with other 
cell types may also play an important role in shaping immune outcomes. Plasmacytoid DC can 
also be matured by gp96, and once mature they are able to suppress HSP-stimulated monocytes 
[88]. Human platelets have also been reported to bind gp96, effectively sequestering this HSP 
from being able to stimulate DC in culture [89]. Limited reports have suggested gp96 may also 
directly stimulate CD4+ T cells [90], due to potential expression of CD91 on these cells [91-93]. 
However, we have been unable to confirm CD91 expression on T cells from mice (Section 3.3.6, 
pg 35).  
2.3 DISCOVERY OF THE HSP RECEPTOR CD91 
Subsequent to the discovery of the immunogenic HSPs, it was observed that these proteins were 
taken up in a highly efficient and specific manner, leading to the hypothesis that a receptor must 
exist [38]. This section details the discovery of the HSP receptor, CD91, as well as the receptor’s 
functions in HSP-mediated immunity.  
2.3.1 Evidence for the HSP Receptor, CD91 
As discussed in Section 2.1.3, simple mixtures of peptide and HSP do not stimulate protective 
immune responses. However, when gp96 is in complex with as little as 1-2 ng of peptide 
protective responses can be observed [28]. We also know HSP-mediated protection is dependent 
on phagocytic cells [66]. Given the rapidity and high efficiency of gp96-mediated responses, it 
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was proposed that professional antigen presenting cells might possess HSP-specific receptors 
[38]. A number of studies supported this hypothesis.  Using gold labeled gp96 particles, Arnold-
Schild showed in 1999 that gp96 is internalized by macrophage- and dendritic-like cell lines via 
clathrin coated pits [94]. Specific binding was then shown on pristane-elicited peritoneal 
macrophages [95], as well as non-elicited, CD11b+ sorted peritoneal macrophages [96]. 
Additionally, fluorescent labeled gp96 binding was associated with cells expressing the 
individual surface markers CD11c, MHC class II, CD45, or Mac-3  from murine splenocytes,  as 
well as human cells expressing HLA-DR, CD86, CD19 or CD14 from peripheral blood [97]. 
The scavenger receptor CD91 was soon identified as the major receptor for HSPs by 
detergent extraction of transmembrane proteins from RAW264.7 cells, a macrophage-like cell 
line, and isolation over a gp96 chromatographic column [98]. Specific binding of gp96 to CD91 
was also observed using biochemical cross-links to transfer radioactive iodine from HSP to the 
receptor [98]. Blocking this receptor with anti-CD91 antibody inhibits the presentation of gp96 
chaperoned peptides to antigen specific T cells, both in vitro (by RAW264.7 cells) and ex vivo 
(by CD11c+ cells) [99]. CD91 has been confirmed as a common endocytic receptor for four of 
the major immunogenic HSPs (hsp70, hsp90, gp96, calreticulin) [22] and has been conserved in 
this capacity across species [100].  
2.3.2 Alternative HSP Receptors 
A number of other endocytic receptors have been implicated as receptors for immunogenic 
HSPs. Reports of CD91 as well as alternative uptake mechanisms are summarized in Table 2-3, 
adapted from our review [23]. The problems with these alternative uptake mechanisms as major 
mechanisms of HSP-mediated immunity have been addressed previously [101]. We do not 
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entirely rule out CD91-independent processes, but we and other laboratories have shown that 
CD91 is the primary transducer of HSP-mediated immunity.  
 
Table 2-3. Reported cross-presenting systems for HSPs and the corresponding uptake mechanism. 
Uptake Mechanism HSPs APC Year Ref. 
Macropinocytosis 
rHSP70 (bovine) bovine mon. 2010 [102] 
rHSP70 (human) 
B-LCL lines L721.45, L721.174, human 
mon. 
2007 [103] 
Receptor mediated & 
macropinocytosis 
gp96 (porcine) 
elicited PEC, RAW 264.7, CHO, COS7, 
BRL 
1999 [95] 
Receptor mediated, not MHC 
class II or DEC205 
gp96 
D2SC/1, D1, BMDC, splenic DC, macs, 
and B cells 
2000 [97] 
Receptor mediated 
endocytosis 
rgp96 BMDC 2011 [104] 
gp96 & HSP70 P388D1, D2SC/1 1999 [94] 
rHSP70 (human) RAW264.7, RAW309Cr.1 2008 [105] 
HSP70 (human) human mon. 2002 [106] 
rHSP70 elicited PEC 2000 [107] 
CD91 
gp96 RAW264.7, PEC  2000 [98] 
gp96, HSP90, HSP70, 
CRT  
BMDCs, PEC  2001 [22] 
gp96 B-LCL, human DC 2004 [108] 
(E.coli & Mtb) hsp70 BMDC, BM-macs 2004 [109] 
CD91 
gp96 RAW264.7, CD11c+ cells 2004 [99] 
α2M Human CD11c+lin- cells 2004 [110] 
gp96 (frog) frog mac-like cells 2008 [100] 
rHSP70 (human) human PBMC 2011 [111] 
CD91 ( not CD14 or TLR4) 
rHSP70 (human), 
rhsp60(human) 
human mon, epidermal LC 2002 [112] 
CD91 (& Other) 
rHSP70 (M.avium 
paratuberculosis) 
BoMac, bovine DC, macs, mon 2005 [113] 
CD91 (& Partial Lox-1, but 
not SRA) 
gp96 
splenic APC, B220+, CD11c+, CD11b+, 
BMDC 
2010 [114] 
CD91 (& Partial CD36/ 
Scavenger Receptor) 
rhsp70 (human) Human mon, mon. derived DC 2010 [115] 
Not CD91 
gp96 (porcine) elicited PEC 2002 [116] 
rgp96 (canine, NTD) MEF-1, PEA-13, DC2.4 2010 [117] 
Receptor mediated & 
macropinocytosis, Not CD91 
gp96 (porcine) elicited PEC, RAW264.7, BMDC 2002 [118] 
Receptor dependent but not 
CD91 or SRA 
HSP90 (human, 
purified), rhsp72 (hum) 
RMA-S/A*2402, BMDC 2007 [119] 
SREC-1 & not CD91 rCRT elicited PEC, DC2.4, MEF-1, PEA-13 2005 [120] 
 16 
Uptake Mechanism HSPs APC Year Ref. 
SREC-1 gp96 (porcine) & rCRT CHO, elicited PEC, BMDC 2004 [121] 
Lox-1 rHSP70 
human myeloid DC, mon., macs, CD19+ 
cells 
2002 [122] 
SREC-1 & Lox-1 rHSP90 (human) BMDC, CHO, HeLa, RAW264.7 2010 [123] 
SRA gp96 (porcine) & rCRT elicited PEC, RAW264.7, HEK 2003 [124] 
SRA (& Other) rgp96 & rCRT fibroblasts, BMDC, BM macs 2008 [125] 
SREC-1 & SRA rgrp170 and rhsp110 RAW264.7, DC1.2, CHO, BMDC 2007 [126] 
Adapted from Table 1 [23]. Cell lines are italicized. Species is mouse unless otherwise indicated. Abbreviations: r, 
recombinant; CRT, calreticulin; NTD, N-terminal domain; mon., monocytes; PEC, peritoneal exudate 
cells/macrophages; macs. macrophages; DC, dendritic; BM, bone marrow derived; LC, Langerhaans cells.  
 
2.3.3 Functions of CD91 in HSP-mediated immunity. 
As described above, CD91 is required for endocytosis of the major immunogenic HSPs. 
Recently, our lab has shown that CD91 is also the major signaling receptor [24]. Phosphorylation 
of the intracellular C-terminal domain of CD91 following HSP:CD91 interaction is required for 
NF-κB translocation and elicitation of cytokines. With this new data, we can now place CD91 in 
the middle of both the innate and adaptive effects of HSPs (Figure 2-3).  
Despite studies showing gp96 binding on assorted cell types, there has been no 
comparison of CD91 expression levels among these cells. It has also been assumed that receptor 
expression would directly lead to uptake of gp96 in vivo, however there may be other 
requirements that could determine specificity of uptake between cell types, such as physical 
access to the sites of extracellular gp96 accumulation or greater baseline levels of endocytic 
activity. Cellular expression of CD91 and its role in determining the cells that endocytose gp96 is 
explored in each of the aims in this research. 
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2.4  CLINICAL TRIALS OF HSPS 
As discussed earlier, the major immunogenic HSPs have shown promising results in murine 
vaccination models [18]. Given these positive results, it is unsurprising that a number of groups 
have tested HSPs in clinical trials. One of the most popular vaccination strategies has been the 
use of autologous, or self-derived, HSPs. Following resection of the patient’s primary tumor, 
HSPs are purified and then used as a therapeutic vaccine against any residual or metastatic 
disease. A comprehensive review of the clinical trials using autologous derived HSPs has been 
 
Figure 2-3. Adaptive and innate immune effects of HSP:CD91 interaction 
This cartoon shows the dual nature of CD91:HSP interaction. To promote adaptive immune responses, CD91 is 
responsible for endocytosis of HSP:peptide complexes and delivery of these complexes to antigen processing 
machinery. Innate effects of CD91, dependent on signaling via tyrosine phosphorylation on the C-terminus, include 
activation and maturation of antigen-presenting cells, secretion of cytokines, up-regulation of co-stimulatory 
molecules, as well as nitric oxide production. 
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published [127], and will be summarized here. Please see Table 2-4 for a complete list of 
autologous gp96 based clinical trials.  
Positive disease outcomes from these clinical trials have been limited, potentially due to 
the advanced nature of most patients’ disease at the time of clinical trial enrollment as well as the 
side-effects of standard therapy on patients’ immune responses. Also, the cumulative therapeutic 
dose of autologous HSPs is variable from trial to trial and even within trials, as it is dependent on 
the amount of tumor tissue available for purification of the HSP. Furthermore, many of these 
Table 2-4. Summary of clinical trials using autologous gp96 
Ref. Year Trial 
Phase 
Tumor 
Type 
Stage # Pts Vaccination Scheme 
[128] 2000 I Varied Late Stage 16 25ug gp96, s.c., weekly, 4x 
[129] 2003 II Colorectal 
carcinoma 
IV 29 2.5, 25, or 100 ug gp96 i.d., weekly, 4x (1st cycle); 
2.5, 25, or 100 ug gp96, i.d., biweekly, 4x (2nd cycle) 
[130] 2002 II Melanoma IV 39 5 or 50 ug gp96, s.c. or i.d., weekly, 4x (1st cycle); 5 
or 50 ug gp96, s.c. or i.d., biweekly, 4x (2nd cycle) 
5 or 50 ug gp96, s.c. or i.d., monthly, 2-3x (3rd cycle) 
[131] 2006 II Melanoma IV 38 25 ug gp96, s.c., weekly, 4x (1st cycle); 25 ug gp96, 
s.c., biweekly, 4x (2nd cycle) 
**Combined with GM-CSF and IFN-α** 
[132] 2008 III Melanoma IV 322 25 ug, s.c., weekly, 4x (1st cycle), biweekly (2nd 
cycle) 
**Randomized to gp96 vs. Physician’s Choice** 
[133] 2010 I/II Melanoma III/IV 36 2.5, 25, or 100 ug, i.d., weekly, 4x 
[134] 2003 II NHL Low grade 10 25 ug, weekly, 4x (1st cycle), biweekly, 4x (2nd 
cycle), biweekly up to 1 year (3rd cycle) 
[135] 2007 II NHL II-IV 20 25 ug, i.d., weekly, 4x (1st cycle) 
25 ug, i.d., biweekly, 4x (2nd cycle) 
[136] 2007 I Pancreatic 
adeno-
carcinoma 
I/II 10 5 ug, i.d., weekly, 4x 
[137] 2008 II RCC II-IV 84 weekly, 4x (1st cycle) 
biweekly, 2x (2nd cycle) 
biweekly +/- IL-2, 4x (3rd cycle) 
Two further cycles +/- IL-2 or repeat of prior cycle 
[138] 2008 III RCC I-IV 728 25 ug, i.d., weekly, 4x (1st cycle) 
25 ug, i.d., biweekly, 4x (2nd cycle) 
[139] 2012 I/II GBM High 
grade 
12 25 ug, 4x, weekly or biweekly, followed by biweekly 
dosing  
This table is adapted from Randazzo et al. Table 2 [127]. Abbreviations: Imm., immune study; QOL, quality of life; 
RCC, renal cell carcinoma; GBM, glioblastoma multiforme; Non-Hodgkin’s Lymphoma; s.c., subcutaneous; i.d. 
intradermal; pts, patients; CR, complete response; SD, stable disease; DFS, disease free survival; TIL, tumor-
infiltrating lymphocytes 
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patients are non-responders to previous therapeutic interventions, and already show 
compromised immune responses. Overall, the safety of gp96-based therapies has been 
impressive, with only mild reactions at the injection site being reported.  Indeed, the worst side-
effects were reported for those studies testing HSP and cytokine combination therapies, where 
the cytokines were the likely causative agent [131,137]. Given that not much is known about the 
in vivo processing events for HSPs following vaccination, there may be a number of targets that 
could be used to improve these clinical outcomes. Gaining knowledge of these targets forms the 
basis for this research.  
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3.0  AIM 1: IDENTIFICATION OF THE CELLULAR SENTINELS FOR NATIVE 
IMMUNOGENIC HEAT SHOCK PROTEINS IN VIVO 
3.1 PREFACE 
Data from this chapter has been published in the Journal of Immunology [140] with myself as 
first author. It is expanded here. Those who performed the experiments detailed in this chapter 
are indicated by their initials in the figure legends (Michelle Messmer: MNM; Robert Binder: 
RJB; Dewayne Faulkner: DF; Yu Zhou: YZ).   
3.2 RATIONALE 
Studies detailing the immunological effects of HSPs have used myriad APCs in vitro, ranging 
from bone marrow derived cells cultured in GMCSF with or without IL-4 [68], peritoneal 
exudates containing macrophages [68], B cells [141], and macrophage- and dendritic-like cell 
lines [142]. Expectedly, the different types of APCs produced a diversity of responses in 
cytokine production and cross-presentation. A compilation of APC subsets and their functional 
relevance to priming adaptive immunity has been reviewed elsewhere [143,144].  
What then are the physiologically relevant APCs necessary for the immunological 
responses elicited by vaccination with HSPs? One experiment performed almost 2 decades ago 
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tested the requirement for APCs during HSP immunization by using the broadly acting reagent 
carrageenan, which inhibits the function of all phagocytic cells; T cell priming was abrogated in 
those studies [66]. One decade ago we showed that CD11c+ cells from lymph nodes of gp96-
immunized mice could transfer tumor immunity, but the phenotype of these cells and whether 
they endocytosed gp96 was not further characterized [72]. More recently, the efficiency of 
priming anti-tumor immune responses with a genetically engineered and secreted form of gp96 
(gp96-Ig) was explored. Those studies showed that intraperitoneal vaccination with these fusion 
proteins caused a dramatic increase of CD11chighMHCIIhighCD103+ cells in the peritoneum [145]. 
While these APCs were able to induce the expression of gut-homing receptor CCR9 in 
responding T cells in vitro, their requirement for priming in vivo was not tested. APC subset 
dynamics with regards to native, murine gp96, following deposition in the skin, as well as their 
expression of CD91, remains unexplored and warrants investigation.   
Following introduction of extracellular gp96 via immunization in mice, gp96 was shown 
to preferentially localize to cells expressing CD11b and CD11c. Subsets of APCs are further 
characterized with respect to CD4, CD8, Gr1.1, MHC class II, F4/80, CD103 and CD207 
expression. Anti-tumor immunity could be transferred to naïve mice by adoptive transfer of cells 
positive for gp96 acquisition. While CD91 expression is essential for gp96 uptake, location of 
APCs within the lymph node was another determining factor for acquiring HSP. These results 
are extrapolated to HSPs in the extracellular environment following active release by, or necrotic 
death of, aberrant cells. This study is important for development of novel HSP-based vaccines 
and for improvement of on-going clinical trials. Finally, these studies will shed light on the 
observations that HSPs are capable of priming Th1 [7,18,66,99,145], Th2 [57,146], Th17 [24] 
and Treg [147,148] responses under different immunization conditions. 
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3.3 RESULTS 
3.3.1 Rapid draining of gp96 to lymph nodes 
For tracking vaccine administered HSPs in 
vivo, apparently homogenous preparations 
of gp96 were labeled with Alexafluor 488 
(A488). We confirmed labeling by SDS-
PAGE and immunoblotting (Figure 3-1A). 
Alexafluor 488-labeled gp96 (gp96A488) 
remained functional as determined by 
binding to and uptake by the CD91-
expressing, macrophage cell line 
RAW264.7. RAW264.7 cells incubated 
with gp96A488 endocytosed significant 
protein as measured by flow cytometry 
(Figure 3-1B) and microscopy (Figure 
3-1C). Gp96, labeled on primary amines in a similar manner, has previously been shown to 
retain its immunological property of priming T cell responses [96].  
Mice were then immunized intradermally with titrated doses of gp96A488. A dose of 1-10 
μg administered via this route has routinely been used to elicit tumor-specific T cell responses 
[7,18,66,99,147]. Single cell suspensions of draining axillary and inguinal lymph nodes (LNs) 
were analyzed by flow cytometry 8 hrs post immunization (Figure 3-2A). Significant A488  
 
Figure 3-1. Purification and labeling of gp96 with Alexa 
fluor 488. 
(A) gp96 was purified to homogeneity, labeled with 
Alexafluor 488 and analyzed by SDS-PAGE and 
immunoblotting. (B,C) Biological integrity of gp96A488 was 
verified by testing its endocytosis by CD91+ RAW264.7 
cells. RAW264.7 were incubated with gp96A488 for 30 mins 
and analyzed by (B) flow cytometry and (C) microscopy. 
Performed by MNM. 
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signal was detected in the lymph nodes at ≥10 μg dose when compared to lymph nodes from 
mice immunized with PBS (Figure 3-3A).  
To analyze the kinetics of gp96A488 appearance in the LNs, we immunized sets of mice 
with 10 g gp96A488 and harvested draining LN at the indicated time points (Figure 3-2B). 
Fluorescent gp96 was observed in the LN as early as 1 hour following immunization and peaked 
 
Figure 3-2. Flow dot plots show increasing A488+ cells with increasing gp96A488 dose in vivo.  
(A) C57BL/6 mice were treated with titrated doses of gp96A488 delivered via intradermal injection. Axillary/brachial 
and inguinal lymph nodes (LN) were harvested 8 hrs later and processed into single cell suspensions for flow 
cytometric analysis. Increasing doses increased the percent of cells positive for A488. Data are representative of 3 
independent experiments, and were quantified in Figure 3-3A. (B) Mice were treated with 10 µg gp96A488 and lymph 
nodes were harvested at the indicated times and processed into single cell suspensions for flow cytometry. Data are 
representative of three experiments, and were quantified in Figure 3-3B. Performed by MNM.  
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at that point (Figure 3-3B). The signal gradually decreased thereafter but was still detectable 72 
hrs post immunization. 
Additionally, we visualized the presence of gp96A488 within LN cells by fluorescent 
microscopy (Figure 3-3C). Two populations of cells differing in the amount of gp96A488 
internalized could be discerned. These results demonstrate that gp96 can be rapidly detected in 
the LN following intradermal immunization and suggests differential uptake by cell populations.  
 
Figure 3-3. Rapid localization of gp96 in lymph nodes following intradermal immunization. 
(A) C57BL/6 mice were treated with titrated doses of gp96A488 intradermally. Draining lymph nodes were harvested 
8 hours later and analyzed by flow cytometry. Results shown are averaged from 3 independent experiments, of 4-8 
mice per group. (B) Lymph nodes from mice receiving 10 μg gp96A488 were harvested at the indicated time points 
and analyzed as above. Data are representative of three experiments, of 5 mice per time point for gp96 group and 2 
per time point for PBS. (C) Lymph nodes from mice receiving 10 μg gp96A488 were harvested at 5 hours, disrupted 
into single cell suspensions and analyzed by microscopy. Nuclei were stained with Hoechst dye (blue), A488 is 
shown in green. Two images at 40x magnification are shown to demonstrate cells with low (yellow arrows) and high 
(white arrows) gp96A488 staining. Data (A,B) are represented as mean +/- SEM. Performed by MNM.  
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3.3.2 Acquisition of gp96 by CD11b+ and CD11c+ cells 
To characterize the cells responsible for the observed gp96A488 signal in the draining LN, we 
adopted a flow cytometric approach including a number of surface markers for APC subsets for 
analysis. Our initial gating strategy was based on a review by Heath et al. showing selective 
characterization of the major APC subsets known at that time (Table 3-1 [143]). As our studies 
progressed, we added additional markers for clarification of APC types and in keeping with 
current publications.  
Our systematic analysis of lymph nodes began with a broad screen based on the surface 
markers CD11c and CD11b, markers associated with professional cross-presenting APCs. The 
experimental gating strategy is outlined in Figure 3-4. The total LN was observed to have ~2% 
CD11c+ cells and ~10% CD11b+ cells (Figure 3-5A). These subsets can be further divided on 
additional functionally relevant markers including MHC class II, CD4, CD8, F4/80, Gr1.1,  
Table 3-1. Major DC Subsets 
DC Subtype 
Surface Marker Expression Tissue Source 
CD11c CD8 α CD4 CD205 CD11b CD45RA 
 
CD8 DC + + - + - - T-cell areas, spleen & LNs 
CD4 DC + - + - + - 
Marginal zone of spleen, 
move once activated 
CD4-CD8- DC + - - - + - 
Marginal zone of spleen, 
move once activated 
Langerhans’ Cell + -/low - +++ + - Skin 
Dermal/ 
Interstitial DC 
+ - - + +/- - 
All tissues 
Plasmacytoid DC low +/- +/- - - + Spleen/blood/ tissues 
Adapted from Heath et al. [143] 
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Figure 3-4. Gating strategy for phenotypic analysis of LN cells. 
(A) Gating of lymph node cells based on forward scatter (FSC) and side scatter (SSC) properties to reduce 
doublets and cell debris, with the final FFC-A by SSC-A gate termed “Total”. Total lymph node cells were 
analyzed directly for surface marker expression or further gated on A488+ cells (B).  (C) Cells were gated on 
CD11b (solid line) or CD11c (red line). (D) CD11b+ and CD11c+ cells were analyzed for their MHC class II 
expression (filled, grey histogram is total lymph node; open, black line histogram is gp96A488+). (E) CD11c+ or 
CD11b+ cells were analyzed for expression of CD4 and CD8. (F) Additional markers analyzed on CD11b+ cells 
were F4/80, Gr1.1, and CD103, with 3 gates (high, med, negative) for each as shown. (G) Additional markers 
analyzed on CD11c+ cells were CD103 and CD207. Gates for all samples were based on single color controls as 
well as “fluorescence minus one.” Shown are representative plots from a minimum of 3 mice for each test. 
Frequencies were quantified and averages are shown in Figure 3-5. Performed by MNM.  
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CD103 and CD207 as shown in Figure 3-4D-G. By applying this analysis to draining LNs 
harvested from mice immunized with 10 μg gp96A488 at 8 or 48 hours after immunization, we 
were able to determine the subsets of cells that contained gp96A488 at each time point.  At 8 hrs, 
CD11b+ cells (CD11c+/-) comprised ~70% of the gp96A488
+ cells (Figure 3-5A). These 
CD11b+gp96+ cells were additionally phenotyped for CD4, CD8, Gr1.1, F4/80, and MHC class 
II (Figure 3-5B, Figure 3-4D-F). CD11b+gp96+ cells were primarily CD4+, CD8-, Gr1.1- with 
low or no F4/80 expression and abundant MHC class II expression (Figure 3-5B). About 30% of 
gp96A488
+ cells in the LN were CD11c+ (CD11b+/-) at 8hrs (Figure 3-5A). These cells were 
further phenotyped for CD4, CD8, CD207, CD103, and MHC class II (Figure 3-4D,E,G). 
CD11c+gp96+ cells also had abundant MHC class II expression, while the expression of CD103 
and CD207 was heterogeneous (Figure 3-5C). A greater percentage of the cells had no CD207 or 
CD103 expression. Cells that were CD11b-CD11c-, comprising the bulk (~93%) of the lymph 
node, accounted for the remaining 30% of gp96A488
+ cells, potentially representing B and/or T 
cells (Figure 3-4C).   
We next compared the overall distribution of cell types with gp96A488 at 8 hrs with those 
at 48 hrs. At 8 hrs, a significantly greater percentage of CD11b+CD4+ cells acquired gp96A488 
compared to CD11b+CD4- cells (Figure 3-5D, Figure 3-4E). CD11c+ cells were a smaller 
fraction of gp96+ cells and included both CD8+ and CD8- cells, though CD8- cells were the major 
CD11c+ fraction. (Figure 3-5D). At 48 hrs post immunization, the distribution of gp96A488 was 
essentially the same (Figure 3-5D,E); CD11b+ cells were still the larger percentage of gp96A488 
compared to CD11c+ cells. However the percentage of gp96A488
+
 that were CD11c
+CD8+ doubled  
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Figure 3-5. Phenotypic analysis of lymph node cells associated with gp96A488. 
Lymph nodes from unimmunized or gp96 immunized mice were analyzed by multi-color flow cytometry as shown 
in Figure 3-4. (A) At 8 hrs post immunization with 10 μg gp96A488, total lymph node and gp96+ cells were 
phenotyped for CD11c and CD11b expression. The CD11c population was CD11b+/- and CD11b+ population was 
CD11c+/-. (B) A488+CD11b+ lymph node cells were additionally phenotyped for CD4, CD8, Gr1.1, F4/80 and MHC 
class II. (C) A488+CD11c+ lymph node cells were additionally phenotyped for CD4, CD8, CD207, CD103 and 
MHC class II. At 8 (D) or 48 (E) hours post immunization with 10 μg gp96A488, lymph nodes were harvested and 
phenotyped for the indicated populations. The distribution of gp96 in each population is indicated as a percentage 
and compared to the percentage of that population in the total lymph node. Percentages are the average from 5 mice, 
and representative of 2 experiments. Data are represented as mean +/- SEM. Performed by MNM.  
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at 48 hrs compared to the 8 hr time point. These data characterize the distribution of gp96 in 
draining lymph nodes following immunization at early and late time points. 
3.3.3 Dose dependent targeting of gp96 
to LN cells 
The dose of gp96 used for immunization 
has a profound effect on the immune 
response generated. At ‘high’ doses, 5-10 
times the ‘optimal’ immunogenic dose 
determined for each route of 
administration, anti-tumor response is 
abrogated by T regulatory cell responses 
[147]. While the immune responses to 
optimal gp96 doses is peptide-dependent, 
the immunosuppression generated by high-
dose gp96 is independent of chaperoned 
peptides. Additionally, high dose gp96 
only suppresses concurrently developing 
immune responses (Figure 3-6). Indeed, 
high-dose gp96 vaccination suppresses any 
active T cell response, and has been used 
as therapy to reverse autoimmunity [148] 
 
Figure 3-6. High dose gp96 suppresses developing 
immune responses. 
After identifying an intradermal immunogenic dose (10 µg) 
and a tolerogenic dose (100 µg), Chandawarkar compared 
the timing and specificity of immunosuppression (Fig. 2 
[148]). (A) Study design; animals were immunized with 
immunogenic dose (purple arrow) and/or a suppressive dose 
(red arrow) or buffer (blue arrow) at indicated time points, 
and challenged with 100,000 Meth A tumor cells (green 
arrow). (B) Tumor growth curves for each of the treatment 
regimens shown in A. N = 5+ mice per group.  
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and to prolong tissue transplant survival [149]. Abrogation of tumor immunity is transferable by 
CD4+CD25+ T cells [148], and the expansion of such regulatory T cells following high dose 
gp96 was shown to outpace CTL expansion and actively suppress effector T cells [150].  
 We were interested in determining whether there are changes in the subsets of LN cells 
targeted by high dose gp96 versus low, ‘optimal’ dose. At 8 hrs post intradermal injection with 
100 µg (‘high’) or 10 µg (‘low’) gp96A488, it appeared that mice given the low dose had an 
increase in the percentage of CD11b+ cells in the lymph node compared to mice injected with 
100 µg (Figure 3-7A), but this was 
not a statistically significant 
difference. Indeed, no differences 
were observed for CD11c+ 
populations, nor for CD4 and CD8, 
despite significantly increased total 
cellularity in LNs from mice injected 
with the high dose (approximately 4 
times more cells compared to dLN of 
mice injected with 10 µg). 
We then analyzed the subsets 
of A488+ cells as described in Figure 
3-4. A dose of 100 µg gp96A488 
resulted in significantly more A488+ 
cells in the total lymph node (~7% 
compared to ~1% in mice injected 
 
Figure 3-7. High dose of gp96 targets alternate cell subsets. 
C57Bl/6 mice were given intradermal injections of 10 µg gp96, 
100 µg gp96 or PBS and draining LNs were harvested 8 hrs later 
and analyzed by flow cytometry as in Figure 3-4. (A) The number 
of CD11b or CD11c cells in the draining LN is expressed as a 
percentage of the total LN. (B) Cells were gated on A488 signal 
and then analyzed for CD11b and CD11c expression. Each 
population is shown as a percent of the total LN.  N=2 mice. 
Performed by MNM.  
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with 10 µg gp96A488). Comparing the expression of CD11b and CD11c on these cells, this 
increase was not evenly distributed among the subsets (Figure 3-7B). The only subset to show a 
significant difference between 100 µg and 10 µg gp96A488 injected mice was CD11c
-CD11b- 
cells (p = 0.01). While APC subsets marked by expression of CD11b and/or CD11c that took up 
gp96A488 only marginally increased, this CD11c
-CD11b- subset increased almost 20 times as a 
fraction of the total LN cells. Thus, there is a large difference in the cells that appear to take up 
gp96 at high doses.  
3.3.4 Gp96 is localized to cells of the subcapsular region of draining LNs 
We used fluorescent microscopy to visualize the location of HSPs in the draining LNs following 
immunization with gp96A488. Mice were immunized with 10 μg gp96A488 and sequential tissue 
sections were prepared 8 hrs post injection. As shown in Figure 3-8, gp96A488 localizes to the 
subcapsular region of the LN. This region is populated primarily by CD11b+ cells, highlighted in 
the region of interest (Figure 3-8B), and is distinct from T cell zones as shown by co-staining for 
CD8 (Figure 3-8C). Overlap of gp96A488 signal with  CD11b and/or CD11c was quantified using 
IMARIS software and substantiates the results obtained by flow cytometry in Figure 3-5; early 
after immunization (8 hrs) gp96A488 is associated more with CD11b
+ than CD11c+ cells (Figure 
3-8D). Draining LN sections from mice immunized with gp96A488 were stained for CD207 
(Langerin) at 8 hrs (Figure 3-8E). A small fraction, of gp96A488 co-localizes to CD207, consistent 
with observations in Figure 3-5C. We next examined the overlap of gp96A488 with CD103, an 
integrin that identifies a subset of LN DC. We observed some co-localization of gp96A488 with 
CD103 although this association was variable (Figure 3-8D,F,G). These data are consistent with 
the flow cytometry data in Figure 3-5.   
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Figure 3-8. Distribution of gp96A488+ cells within the LN. 
Mice were immunized with 10 μg gp96A488 and draining LNs were harvested 8 hrs later and analyzed by fluorescent 
microscopy. Green indicates gp96A488 fluorescence and blue is Hoechst nuclear staining. (A) Images captured at 10x 
magnification. Region of interest (ROI, red box) was selected for further analysis. (B) ROI is analyzed for CD11b 
(red) and CD11c (white).  (C) Image at 20x magnification showing CD8 stain to reveal T cell zones. (D) Images 
were analyzed using IMARIS and the co-localization of each marker indicated with gp96A488 was quantified and 
expressed as percent A488+ above threshold that co-localized. Each marker (red or white) was analyzed separately 
and there is potential overlap with other indicated markers. Data are the average value from 3 ROIs analyzed. Data 
are represented as mean +/- SEM. (E) Sections at 20x magnification were stained for CD207. Co-localization of 
CD207 with gp96A488 was quantified (D). (F) Sections at 40x magnification were stained for CD103 (red). (G) ROI 
from (F) showing co-localization of CD103 (red) with gp96A488 (green). Co-localization was quantified (D). Images 
and calculations are representative of 2 independent experiments.  Performed by MNM.  
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3.3.5 Functional gp96+ APCs transfer tumor-specific immunity  
As shown in previous studies conducted in vitro, gp96 stimulates APCs rendering them capable 
of providing signals for priming T cells. In addition, peptides (including tumor antigens) 
chaperoned by gp96 are cross-presented by the same APCs. We set up an antigenic system based 
on the CMS5 tumor and its immuno-dominant peptide ERK [151], to test whether the APCs that 
captured gp96 in vivo were immunogenic (Figure 3-9A). Gp96A488 was complexed to the ERK 
peptide (gp96A488-ERK) or left uncomplexed (gp96A488). Mice were immunized with 10g of 
gp96A488-ERK, gp96A488, ERK peptide alone or PBS. Draining LN cells were harvested from 
each group of mice after 6 hrs and A488+ cells were isolated by FACS (Figure 3-9B). A488+ 
cells from gp96A488-ERK or from gp96A488 group, or bulk lymph node cells from ERK peptide or 
PBS immunized group, were transferred to naïve BALB/c mice retro-orbitally. Recipient mice 
were challenged one week later with CMS5 cells and tumor growth rate was measured (Figure 
3-9C).  
Tumor growth was significantly retarded only in mice that received A488+ cells from 
donors immunized with gp96A488-ERK. Tumors grew with identical kinetics in mice receiving 
A488+ cells from donors immunized with gp96A488, or mice receiving bulk LN cells from donors 
immunized with ERK peptide or PBS (Figure 3-9C). We tested whether the protective effect was 
dependent on the cross-priming ability of donor (A488+ cells) or recipient APCs. Cells from 
donors immunized with gp96A488-ERK or gp96A488 were irradiated prior to adoptive transfer to 
recipient naïve mice as above. Recipients were then challenged with CMS5. Tumor growth rate 
was measured (Figure 3-9D). The protective effect of A488+ cells from gp96A488-ERK 
immunized mice was abrogated when the cells were irradiated, as the tumors grew with identical 
kinetics to control treated or untreated mice. This demonstrates that the transferred (donor) APCs 
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were actively involved in priming anti-tumor immunity through events that may include antigen 
transfer, cross-presentation and migration.  
 
Figure 3-9. Adoptive transfer of tumor immunity by gp96A488+ lymph node cells. 
(A) A schematic of adoptive transfer of tumor immunity. Groups of mice were immunized with gp96A488-ERK or 
gp96A488. Draining lymph nodes were harvested 6 hours later. Gp96A488+ cells were purified by FACS and 
transferred to naïve mice. Whole lymph node cells from mice immunized with ERK alone or PBS were transferred 
into other naïve mice. Recipient mice were challenged with CMS5 tumor 1 week later. Tumor growth was 
monitored. (B) Representative FACS plots showing gated cells that were transferred. (C) CMS5 growth curves in 
recipient mice following transfer of donor cells. Average values calculated from 2-8 recipient mice from 2 
independent experiments.  *p < 0.05, compared to gp96A488 recipients. (D) CMS5 growth curves in recipient mice 
following transfer of irradiated donor cells. Average values are from 2-5 recipient mice per group. Primarily 
performed by MNM with help from DF (cell sorting), RJB (retro-orbital adoptive transfer), and YZ (tumor cell 
challenge).  
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3.3.6 Differential expression of CD91 in APC subsets. 
We have previously shown that CD91 expression is essential for gp96 uptake. Thus we tested the 
relative expression of CD91 by APCs in the LN as characterized by their expression of CD11b 
and/or CD11c (Figure 3-10A). Cells were stained for CD91 simultaneously with CD11b and 
CD11c and analyzed by flow cytometry. CD91 expression was observed to vary with each 
population (Figure 3-10B, Figure 3-10A-C). CD11c+CD11b+ cells had the most robust CD91 
expression as measured by geometric MFI followed by CD11c-CD11b+ cells. CD91 expression 
on CD11c+CD11b- cells, while barely detectable, was still significant over background staining 
with secondary antibody alone. CD91 expression was not significantly detected on CD11c-
CD11b- cells in this assay although this observation does not conflict with the possibility that a 
 
Figure 3-10. Expression of CD91 on subsets of APCs in the lymph node. 
Lymph node cells were analyzed by multi-color flow cytometry for CD11b, CD11c, and CD91. (A) Cells were first 
gated on CD11b and CD11c subsets, and then the average geometric mean fluorescence intensity for CD91 was 
quantified for each population and compared to secondary alone (B). Data are averages for three mice +/- SEM, and 
representative of 3 experiments. (C) CD91 expression on CD11c/CD11b populations was confirmed by FACS 
sorting followed by SDS-PAGE and immunoblotting. CD91 -chain (85 kDa) is identified by the arrow. Positive 
and negative control cell lines for CD91 were RAW264.7 and EL.4 respectively. Performed by MNM with help 
from DF (cells sorted for C).  
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minor cell type in this large and varied population does so [90,93]. The results in Figure 3-10B 
were confirmed by immunoblotting. FACS purified APC populations from the lymph node were 
lysed and analyzed by SDS-PAGE and immunoblotted for the -chain of CD91 (85kDa). CD91 
expression was easily detectable in CD11c+CD11b+ populations and more difficult to discern in 
CD11c-CD11b+ and CD11c+CD11b- populations (Figure 3-10C). The macrophage cell line 
RAW264.7 served as a positive control and EL.4 thymoma cells as the negative control for 
CD91 expression. 
3.3.7 CD91 expression correlates with superior gp96 endocytic capacity  
To determine the endocytic capacity of LN cells for gp96, we harvested naïve LNs, processed 
the cells into single cell suspensions, exposed these cells to sub-saturating levels of gp96A488 in  
 
Figure 3-11. Histograms of CD91 expressing APC subsets.  
Lymph node cells were analyzed by multi-color flow cytometry for CD11b, CD11c, and CD91. Cells were first 
gated on CD11c or CD11b expression as in Figure 5A.  (A) The fluorescence intensity of CD91 (solid black line) 
versus secondary antibody alone (filled histogram) is shown for each gated population. Average geometric mean 
was quantified for each population from three mice was quantified for Figure 5B. (B) Alternative gating on CD11c 
high, intermediate, or negative cells followed by CD11b gating was conducted to investigate CD91 expression on 
migratory versus resident cells. (C) Fluorescence intensity of CD91 (solid line) versus secondary alone (filled 
histogram) is shown for each subset. Performed by MNM.  
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Figure 3-12. Differential capacities of APC subsets to endocytose gp96. 
(A) Isolated lymph node cells were incubated with titrated doses of gp96A488. Cells were analyzed by flow cytometry 
for A488 positivity and expressed as a percentage of the total population. (B) The lymph node cells were gated into 
populations expressing CD11c+ and/or CD11b+. (C) Following incubation of lymph node cells with varying doses of 
gp96A488, these populations were analyzed for endocytosis of gp96A488. Experiments were performed in duplicates. 
(D) Endocytosis of gp96A488 by the indicated populations was tested by incubating lymph node cells with 20 nM 
gp96A488 for the indicated time. Experiments were performed in duplicates. (E) Competitive endocytosis was 
examined by mixing purified populations of CD11b-CD11c+ and CD11b+CD11c+ cells with sub-saturation amount 
of gp96A488. A representative FACS plot of the cell mixture is shown. (F) An analyses of the two populations of cells 
from (E), for A488 positivity are presented as histograms. (G) Competitive endocytosis was examined by mixing 
purified populations of CD11b+CD11c- and CD11b+CD11c+ cells in the presence of sub-saturation amount of 
gp96A488 cells. A representative FACS plot of the cell mixture is shown. (H) An analysis of the two populations of 
cells from (G), for A488 positivity are presented as histograms. (I) The endocytosis of sub-saturating amounts of 
gp96A488 by CD11b+CD11c+ cells, in the presence or absence of CD11b+ cells, is shown. Data (A,C,D) are 
represented as mean +/- SEM. Performed by MNM with help from DF (cell sorting).  
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vitro and analyzed them by flow cytometry (Figure 3-12). Consistent with the data in Figure 
3-3A, the percent of gp96A488
+ cells was titratable with increasing amounts of gp96A488 (Figure 
3-12A). LN cells were phenotyped for CD11b and CD11c expression (Figure 3-12B). Regardless 
of the amount of gp96A488 provided, CD11b
+CD11c+ cells endocytosed the most gp96A488 as 
measured by geometric mean fluorescence intensity (Figure 3-12C); cells expressing the highest 
levels of CD91 (Figure 3-11). As a population, CD11c-CD11b- cells appeared to acquire very 
little gp96A488 (Figure 3-12C), correlating with their lack of CD91 expression. In addition, 
incubations of cells with gp96A488 for different lengths of time did not change the outcome; 
significantly more gp96A488 was associated with CD11c
+CD11b+ cells than other cells at all time 
points measured (Figure 3-12D). 
We next investigated the efficiency of gp96A488 uptake in competition studies by isolating 
each cell subset and performing the same experiment with individual or mixed combinations of 
cells in sub-saturating concentrations of gp96A488. LN cells were sorted into CD11c
+CD11b- or 
CD11c+CD11b+ populations. These two populations were mixed in comparable numbers (Figure 
3-12E) and incubated with gp96A488. Cells were analyzed by flow cytometry for gp96A488 
incorporation (Figure 3-12F). CD11c+CD11b+ cells were observed to incorporate significantly 
more gp96A488 than CD11c
+CD11b- cells. A similar experiment was performed with isolated 
CD11c+CD11b+ cells mixed with CD11b+CD11c- cells (Figure 3-12G). CD11c+CD11b+ cells 
were again observed to incorporate significantly more gp96A488 than CD11b
+CD11c- cells 
(Figure 3-12H). The acquisition of gp96A488 by CD11c
+CD11b+ cells was unaffected by the 
presence (mixed) or absence (unmixed) of other CD91+ (CD11b+CD11c-) cells (Figure 3-12I). 
We thus conclude that CD11c+CD11b+ APCs, characterized by robust CD91 expression, appear 
superior at endocytosis of gp96 compared to other LN cells with lesser or no CD91 expression.  
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3.3.8 Loss of CD91 on CD11c+ cells does not alter early gp96+ subsets.  
Given that CD91 is required for uptake of HSPs, we were interested in determining if CD91 loss 
would alter the subsets targeted by vaccination. CD11c-specific CD91 KO mice were generated 
as described in Materials & Methods and are further characterized in Aim 2. CD91 KO mice and 
Cre- littermates were given intradermal injections with 10 µg gp96A488. Draining LN cells were 
then harvested 8 hrs later and analyzed by flow cytometry as previously described (Figure 3-4). 
A trend was observed toward an increased percent of gp96A488
+ cells in the LN of CD91 KO 
mice, but this did not reach significance (Figure 3-13A). Comparing the ratios of CD11b+ cells in 
the total LN and gp96+ cells, there was no difference between CD91 KO and WT in the total LN 
but a trend toward a decrease in CD11b+ cells for the gp96+ subset of CD91 KO mice was 
observed (Figure 3-13B). No differences were observed for CD11c+ subsets (Figure 3-13C), or 
for other markers tested (not shown). Thus, despite CD91 deficiency on CD11c+ cells, uptake at 
early time points in the draining LN was unaffected.   
 
Figure 3-13. Initial uptake of gp96 in dLN is not altered in CD91 KO mice. 
(A) CD91 KO mice injected with 10 µg gp96A488 show slightly higher levels of A488+ cells in dLN compared to WT 
mice 8 hours after i.d. injection. (B) LN cells were analyzed for CD11b expression. The percent of CD11b+ cells 
from the total LN population vs. the gp96+ population is compared for WT and KO. (C) LN cells were analyzed for 
CD11c expression. The percent of CD11c+ cells from the total LN population vs. the gp96+ population is compared 
for WT and KO. No significant differences were detected for any markers tested. N = 4 WT, 4 KO.  One of two 
representative experiments shown. Performed by MNM.  
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3.4 DISCUSSION 
We and others have routinely tested the cross-presentation of HSP-chaperoned peptides and 
provision of co-stimulation by APCs in vitro [22,24,68,96-98,100,106,109,114,152]. Recent 
observations that HSPs can prime diverse T cell and B cell responses [7,24,57,146-148] suggest 
that immune responses can be skewed by the responding APC, as shown in other settings [143]. 
This appears to be dependent on the sum total of co-stimulation and efficiency of peptide cross-
presentation by APCs.  
This chapter characterizes the APCs relevant for HSP-mediated immune responses. Cells 
that acquired gp96 predominantly express CD11c and/or CD11b in the LN. These populations 
included CD11c+CD11b+ cells which have been described as LN resident APCs [153,154]. 
CD11cint (CD11b-) cells, compatible with migratory APCs were included in the gp96+CD11c+ 
population. However, other markers of migratory APCs such as CD207 and CD103high were a 
minor percentage of the total gp96+ population suggesting migratory APCs play a small role in 
early gp96 trafficking. Since CD207 analysis was performed at 8 hrs post immunization our 
observations do not rule out a greater role for migratory cells in gp96 trafficking at later time 
points. Interestingly, distribution of gp96 in CD11c+ cells changed slightly with time, increasing 
in CD8+ cells at a later time point. However more gp96 appeared to associate with CD11b+ than 
CD11c+ cells at both time points.  
Several mechanisms may explain this observation and are not mutually exclusive; First, 
CD11b+ cells are the densest population of cells along the periphery of the LN. These would be 
the first cells in contact with draining protein [155] and thus, would have preferential access to 
gp96 regardless of their rate of incorporation. Once gp96 begins to accumulate, CD11c+ cells 
migrating to the edge of the LN may gain access. Second, gp96 may be transferred between cells 
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through a variety of mechanisms including intercellular communication [156], CD91 dependent 
capture of extracellular gp96 [157], or capture of vesicle encapsulated material [158,159]. Thus 
CD91+CD11b+ cells may transfer endocytosed gp96 to other cell types over time. Third, 
macrophages are known to rapidly degrade internalized material while dendritic cells do this at a 
slower rate [160]. Extended times beyond 48 hrs may favor accumulation of gp96 in CD11c+ 
cells. Fourth, we have not ruled out an influx of migratory cells from the periphery at later time 
points although changes in the total cell distribution in lymph nodes at 48 hrs were subtle. Our 
findings can be compared to previous studies showing an increase in 
CD11chighMHCIIhighCD103+ APCs following intraperitoneal vaccination with gp96-Ig fusion 
protein [145]. However, since the vaccination site, draining lymph nodes, and immunizing 
protein (native gp96 vs gp96-Ig) are different, it was anticipated that only a partial overlap of 
relevant APCs subsets would be observed. 
Regardless of CD11b and/or CD11c expression, the robust expression of MHC class II on 
cells acquiring gp96 attests to the peptide presenting ability of these cells. We have successfully 
transferred anti-tumor immunity between mice through the adoptive transfer of gp96+ cells. 
Gp96+ cells are predominantly CD11b and CD11c expressing cells. While there may be 
contaminating cells not expressing these markers in the transferred population, the low numbers 
of total transferred cells renders these potential contaminating cells marginal. Transferred cells 
elicited antigen-specific tumor immunity in recipient mice only when viable suggesting that 
donor cells must be cross-priming competent.  
Overall, we have resisted applying the nomenclature ‘macrophage’ and ‘dendritic cell’ to 
our CD11b+ and CD11c+ populations and we compare them with caution to previously 
characterized APC subsets [143,144,153,154,161] for the reason that there are examples of 
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CD11b and CD11c expression on both macrophages and dendritic cells. Where appropriate, we 
have drawn parallels to previously characterized cell types using additional markers to clarify the 
phenotype of cells described in our study.  
Both CD11c+ and CD11b+ cells express some level of CD91 which satisfies one 
requirement for interaction with, and uptake of, HSP [22]. We demonstrate that CD91 expression 
closely correlates with ability of APCs to endocytose gp96. CD11c+CD11b+ cells which have 
been characterized as LN resident APCs [153] express CD91 which is reflected in their superior 
ability to endocytose gp96. CD11c+CD11b- cells, including CD11cint (or migratory APCs) 
express less CD91 and are expectedly less efficient at endocytosis of gp96 than CD11c+CD11b+ 
cells. These results were largely consistent both in vivo and in vitro; in vitro, when gp96 is 
abundant and access to cells is not restricted, CD11c+CD11b+ APCs appear to be superior in 
taking up gp96. In vivo, gp96 would be accessible to CD11c+CD11b+ cells following diffusion of 
gp96 through the lymphatics, however we have not ruled out transfer of gp96 to these cells from 
migratory cells. The CD11c-CD11b- population, in our in vitro and low dose in vivo experiments, 
also performs as expected based on observed CD91 expression levels. However, the observation 
of increased uptake of gp96 by these cells in vivo following administration of high, 
immunosuppressive doses of gp96 was unexpected. We have not ruled out the potential 
recruitment of immature cells to the LN following high dose administration. We are also 
investigating changes in expression of CD91 following inflammatory stimulation that may 
address this difference; perhaps this subset, after prolonged exposure to high levels of gp96 
experiences induced CD91 (Aim 3). Our finding that KO of CD91 on CD11c+ cells had little 
effect on cells in the LN that take up gp96 may be due to incomplete loss of CD91 on the 
predominately CD11b+ population, which expresses only low levels to no CD11c.  Additional 
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factors that may contribute to the final cross-presentation of HSPs in vivo, such as retention of 
endocytosed material, remain to be examined.  
The identification of physiologically relevant APCs for HSP-mediated immunity has 
important implications for designing vaccines to cancer and infectious disease. However, these 
studies also impact our understanding of effects of extracellular HSPs resulting from necrotic 
lysis of cells in tumor microenvironments or cell lysis associated with pathogen infection and 
trauma [68]. Thus release of gp96 from cells and its rapid drainage to regional LNs will serve to 
alert the immune system of cellular compromise. In the setting of immune surveillance, this 
mechanism may be responsible for the observed anti-tumor immunity associated with 
tumorigenesis. These studies identify a crucial step in priming HSP-associated immune 
responses. 
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4.0  AIM 2: EXAMINATION OF IMMUNE RESPONSES INDUCED BY HEAT 
SHOCK PROTEINS RELEASED FROM TUMOR CELLS  
4.1 PREFACE 
Some of the data in this chapter is part of a manuscript that has been favorably reviewed by the 
journal Cancer Immunology Research and is here included with permission from the primary 
author, Yu Zhou. I am the second author on this manuscript. Those who performed the 
experiments detailed in this chapter are indicated by their initials in the figure legends (Michelle 
Messmer: MNM; Yu Zhou: YZ; Robert Binder: RJB).   
4.2 RATIONALE 
Adaptive immune responses against tumors are routinely detected in tumor bearing hosts. In 
cancer patients and in murine experimental tumor systems, recognition of tumor by the host’s 
immune system results in priming of concomitant immunity and immunoediting [162-164]. 
Conventional mechanisms of priming immune responses to pathogens do not generally apply to 
tumors because, wherever tested, tumors generally lack sufficient antigen as a native protein for 
cross-priming [165,166]. In addition, being of self-origin, tumors largely exist in a sterile 
environment lacking the classical pathogen-associated molecular patterns that give rise to innate 
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immune activation and provision of co-stimulation necessary for priming T cells. Given the 
ability of endogenous, purified HSPs to efficiently prime specific immune responses under 
conditions of limiting antigen [7,166] we tested the role of tumor-derived HSPs in situ and their 
receptor CD91 in initiation of immune responses to tumors.  
We have explored the HSP-CD91 axis as a mechanism for host priming of anti-tumor 
immunity for two reasons; 1) antigens in the form of peptides are chaperoned by HSPs and are 
efficiently cross-presented by APCs [28,53,65,108,114]. The increase in efficiency of cross-
presentation of HSP-chaperoned peptides versus peptides alone, is several thousand fold and is 
made possible through the cell surface receptor CD91 on antigen presenting cells 
[22,98,99,109,111,166]. 2) We have recently shown that HSPs signal through CD91 to activate 
APCs to provide co-stimulation through secretion of pro-inflammatory cytokines including IL-
1β, TNF-α, IL-6 and increased expression of CD40, MHC class II and CD86 [24,68,84,167].  
The immunological properties of HSPs make them prime candidates for the initiation of 
immune responses to tumors. However, HSPs are necessary for cell survival so testing their 
requirement for priming tumor-specific immune responses in vivo through simultaneous or 
sequential deletion is not possible. Instead, we tested their requirement by targeting and 
selectively blocking the HSP receptor CD91. This approach is possible because, while 
structurally unrelated, four of the immunogenic HSPs (gp96, hsp90, hsp70 and calreticulin) 
utilize the same receptor CD91 to elicit immune responses [22,24,98,99,101]. We show that, 
unlike wild type mice, mice lacking CD91 expression on CD11c+ cells have reduced anti-tumor 
immune responses. These responses can also be abrogated by the receptor associated protein 
(RAP), an endogenous inhibitor of the HSP-CD91 pathway, which prevents exposed HSPs from 
binding to CD91. Expression of RAP by tumor cells reduces the localization of fluorescent 
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labeled gp96 in tumor-draining LNs. Our findings demonstrate that early in tumor development, 
the HSP-CD91 pathway is critical for establishment of anti-tumor immunity. 
4.3 RESULTS 
4.3.1 Characterization of APC from CD11c-specific CD91 KO mice 
Conventional CD91 knock-out mice are embryonically lethal [168], thus we created mice 
lacking CD91 expression in CD11c+ cells. To test the requirement for CD91 in gp96-mediated 
 
Figure 4-1. Phenotyping of CD91 KO mice. 
Data from Zhou, et al. (A) Cre+ and Cre- BMDC purified to 96% CD11c+ were analyzed by western blot for their 
expression of CD91. (B) Immune cell populations from Cre+ and Cre- lymph nodes were analyzed by flow 
cytometry. (C) BMDC generated from Cre+ or Cre- mice were stimulated with LPS for 24 hours (black line) and 
activation marker expression was analyzed by flow cytometry, compared to unstimulated (blue line). Performed by 
RJB.  
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anti-tumor immunity, CD11cCre mice were bred to CD91flox mice to generate mice lacking 
CD91 on their CD11c+ cells (CD91 KO mice). For more information on the CD91 KO mice, see 
“Material & Methods 7.1.1 Generation of CD11c specific CD91 knockout mice,” pg. 77. CD91 
KO BMDCs were generated as described and purified by magnetic activated cell sorting on 
CD11c expression (purity = 96%). Lack of CD91 expression was confirmed by SDS-PAGE and 
immunoblotting for CD91 protein expression (Figure 4-1A). Analysis by flow cytometry showed 
CD91 KO mice had equal percentages of CD4 and CD8 T cells, B cells, macrophages and DCs 
compared to Cre- littermates (Figure 4-1B). Maturation of CD91 KO BMDCs was tested by 
pulsing with LPS for 24 hours and measuring expression of CD86, CD40 and MHC class II by 
flow cytometry (Figure 4-1C). All were up-regulated in response to LPS, comparable to 
increases seen for Cre- littermates. CD91 KO BMDCs were also able to respond to LPS by 
secreting IL-1β, however, they failed to secrete IL-1β in response to gp96 (not shown), 
consistent with our previous observations [24,68].  
 
Figure 4-2. CD91 is required for priming anti-tumor immune responses. 
Data from Zhou, et al. (A) CD91 KO mice or Cre- littermates were challenged intradermally with D122 tumor cells, 
average tumor diameter from tumor measured on two axes shown. (B) CD8+ T cells were depleted from CD91 KO 
mice or CD91 Cre- littermates 24 hours prior to implantation of intradermal D122. CD8 depletion was continuous for 
>5 days. Tumor growth was monitored as in (A). (C) SVB6 tumor was implanted intradermally into CD91 KO mice 
or CD91 Cre- littermates. Tumor growth was monitored as in (A).  n.s., not significant; * P< 0.05. Experiments were 
performed multiple times with 3-5 mice per group. Performed by YZ.  
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4.3.2 Loss of CD91 expression on CD11c+ cells abrogates anti-tumor immunity 
To test the requirement for CD91 expression on CD11c cells in initiating anti-tumor immunity, 
we tested tumor growth rates in the CD11c-specific CD91 KO mice. After inoculating mice with 
8x105 cells of the moderately immunogenic Lewis Lung Carcinoma, D122, tumor growth rate 
was significantly faster in CD91 KO mice versus Cre- littermate controls early after initial 
challenge and through day 11 (Figure 4-2A). After day 11, tumor growth rates were comparable.  
To determine the role of adaptive immune responses, we depleted CD8+ T cells from the CD91 
KO mice or Cre- littermate controls. In the absence of CD8+ cells, D122 tumors grew with 
identical kinetics in both groups (Figure 4-2B). This tumor growth was identical to the growth 
observed in CD91 KO mice in Figure 4-2A. These results suggest that CD8+ T cell priming was 
impaired in CD91 KO mice. We tested the generality of these observations by monitoring tumor 
growth for the highly immunogenic, regressor SV40-transformed tumor SVB6. While SVB6 
grew and was rejected in both CD91 KO and Cre- littermate controls, the tumors grew 
significantly larger and were rejected more slowly in CD91 KO mice (Figure 4-2C).  
4.3.3 Expression of gp96EGFP construct in tumor cells. 
We have previously shown that HSPs are a necessary and sufficient source of antigen to prime 
CD8 T cells [166], thus we investigated the release of HSPs from growing tumors as the source 
of antigen for priming that is blocked by loss of CD91.  To track the release of HSPs from 
growing tumors in vivo, we constructed a gp96EGFP fusion protein as described in Materials & 
Methods. This construct was transfected into the CMS5 tumor cell line and, after growth in 
selective media, was found to be stably expressed. A 25 mL cell pellet was collected  
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from CMS5 gp96EGFP cultures and gp96 was purified as previously described [28]. SDS-PAGE 
and Western Blotting analysis of the final purification fractions showed that gp96EGFP retained 
the same biochemical properties as endogenous gp96 and is expressed at comparable levels 
(Figure 4-3A). By growing these cells on coverslips, we were able to analyze the intracellular 
localization of gp96EGFP. Our construct included the ER retention sequence,  
KDEL, on its C-terminus allowing for recognition by ER sorting machinery [169]. Indeed, 
gp96EGFP was found to co-localize with Protein Disulfide Isomerase (PDI), a marker for the 
endoplasmic reticulum, but did not co-localize with Hsc70, normally expressed in the cytosol 
 
Figure 4-3. gp96EGFP co-purifies and co-localizes with endogenous gp96. 
Gp96 was purified from frozen gp96EGFP-expressing CMS5 tumor cell pellet after dounce homogenization. 
Purification was performed according to previously published methods (see Materials & Methods). (A) Individual 
fractions from the final chromatography separation (DEAE) were analyzed by SDS-PAGE. Equivalent protein 
amounts of endogenous gp96 (96 kDa) and gp96EGFP (130 kDa) were measured in each fraction by Coomassie 
staining (top) and Western blotting with anti-gp96 antibody (middle). Only one major band was observed at 130 kDa 
when probed with anti-EGFP antibody (bottom). (B) CMS5 cells expressing gp96EGFP (green) were cultured on glass 
coverslips and then stained with either anti-PDI antibody (top, red) or anti-Hsc70 antibody (bottom, red), as well as 
phalloidin (white) and Hoechst (blue). Performed by MNM.  
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(Figure 4-3B). This data shows that gp96EGFP shares biochemical features and cellular 
localization with endogenous gp96. 
4.3.4 CMS5 retain detectable gp96EGFP expression after tumor growth in vivo.  
Expression of exogenous antigens such as EGFP may induce immune responses, increasing 
selective pressure on tumors in vivo to lose expression of this antigen. We were interested in 
 
Figure 4-4. gp96EGFP expression by CMS5 tumors in vivo. 
(A) Mice were intradermally challenged with 5x106 wild type CMS5 cells (top) or CMS5 cells expressing gp96EGFP 
in the dorsum and followed 8 days. Tumors were harvested, sectioned in two and processed for microscopy and flow 
cytometry. Samples for microscopy were fixed, and prepared in sucrose as described in Methods (pg. 84). Sections 
were stained for CD11c (white), Hoechst (blue), and CD4 or CD8 (red). Expression of gp96EGFP is shown as green. 
(B) Tumor cells were dissociated into single cell suspensions and analyzed for EGFP by flow cytometry; 
untransfected CMS5 (filled histogram) vs. gp96EGFP CMS5 (black line). (C) Draining LN were analyzed by flow 
cytometry for EGFP+ cells; untransfected CMS5 (red) vs. gp96EGFP CMS5 (black). Performed by MNM.  
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determining the long-term expression of gp96EGFP by CMS5 tumor cells in vivo. BALB/c mice 
were intradermally challenged in the dorsum with 5x106 untransfected CMS5 cells or CMS5 
cells expressing gp96EGFP. At day 8, tumors and draining LNs (axillary and inguinal) were 
harvested and analyzed by microscopy and flow cytometry for presence of EGFP. Both 
untransfected CMS5 and gp96EGFP expressing CMS5 tumors showed infiltration by CD4
+ cells  
but lack of infiltration by CD8+ cells (Figure 4-4A). A small 
number of CD11c+ cells were also detectable in both tumors. 
As seen by microscopy, CMS5 retained expression of gp96EGFP 
at 8 days post implantation. This was also detectable by flow 
cytometry of single cell suspensions of the tumor isolates 
(Figure 4-4B). Comparing single cell suspensions from 
draining LNs from the tumor bearing mice, no difference in 
gp96EGFP was detectable 8 days post tumor implantation 
(Figure 4-4C). This is likely due to the number of LNs draining 
the dorsal region and the limited amount of protein expected to 
be spontaneously released.  
In order to reduce the number of LNs draining the tumor environment, we switched to 
footpad injections and harvested the popliteal LNs for analysis. We also gated on CD45 
expression in the draining LN to reduce the possibility of tumor cells that may either migrate or 
drain to LNs after injection. Due to minor variations in auto-fluorescence observed in each 
mouse and in the fluorescence intensities for each gp96EGFP expressing cell line (Figure 4-5), the 
signal was normalized to these two parameters by accounting for background signal in  
 
Figure 4-5. Expression of EGFP 
prior to tumor challenge.  
Data from Zhou et al. CMS5 cells 
were harvested, washed in PBS, and 
analyzed by flow cytometry for 
EGFP expression prior to tumor 
challenge. Representative 
histograms for one experiment 
showing CMS5 gp96EGFP co-
expressing RAP (solid line) or β-
galactosidase (irrelevant protein, 
dashed line). Performed by YZ.  
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Figure 4-6. Measurement of EGFP fluorescence intensity in draining LN. 
Data from Zhou et al. CMS5 cells expressing gp96EGFP and either RAP or β-galactosidase as an ‘irrelevant’ protein 
were implanted into the footpad of BALB/c mice for two days before draining lymph nodes were isolated, stained 
for CD45, and analyzed by flow cytometry for EGFP. (A,B) Representative histograms showing the EGFP+CD45+ 
cells in the non-draining LN (ndLN) or draining LN (dLN) of tumor-bearing BALB/c mice (A) or CD91 KO mice 
(B). (C,D) MFI of all mice from one experiment are shown. (E) Formula for calculating the normalized EGFP signal 
taking into account autofluorescence of LN cells and the starting fluorescence of each cell line.  Performed by YZ.  
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contralateral, non-draining popliteal lymph nodes and fluorescence of gp96EGFP expressing cells 
on the day of the experiment, respectively (Figure 4-6).  
4.3.5 CD91 is required for uptake of immunogenic HSPs  
To determine whether CD91 was essential for tumor-derived HSPs draining to the LN, gp96EGFP 
expressing CMS5 cells were doubly transfected with RAP, an endogenous inhibitor of CD91-
HSP interaction, or control, ‘irrelevant’ protein β-galactosidase. BALB/c mice were challenged 
in the footpad and tumors were grown 2 days before harvesting draining and non-draining 
popliteal LNs. EGFP fluorescence was measured by flow cytometry as described (Figure 4-6). 
Significantly less EGFP was detected in LNs draining tumors co-expressing RAP compared to 
control protein (p = 0.0002, Figure 4-7A). 
Additionally, we tested the draining of gp96EGFP to LNs in CD91 KO mice using the 
same system. CMS5 cells expressing gp96EGFP with or without RAP were implanted in footpads 
 
Figure 4-7. Draining of gp96EGFP blocked by RAP.  
BALB/c mice (A) or CD91 KO mice (B) were implanted with 5x106 CMS5 cells expressing gp96EGFP with or 
without RAP in the footpad. Draining and contralateral, non-draining lymph nodes were harvested two days later. 
LN cells were stained CD45 and analyzed by flow cytometry for EGFP. EGFP signal was normalized against 
starting fluorescence for each cell line and the background fluorescence of non-draining lymph nodes. ***p < 
0.001. Experiments were performed 2 times with 8 mice per group in (A), or 3 mice per group in (B). Error bars 
indicated SEM. Performed by YZ.  
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of CD91 KO mice. Again, draining LNs were 
harvested after 2 days and analyzed as in Figure 
4-6. We did not detect gp96EGFP signal in CD91 
KO LNs whether or not tumors expressed RAP 
(Figure 4-7B). The importance of CD91 for HSP 
transfer and trafficking is thus highlighted in cases 
of deficient expression in APCs and antagonism 
via RAP. HSP-mediated vaccine response is 
abrogated in CD11c-specific CD91 KO mice. 
We tested the response of CD91 KO mice to gp96 immunization in a prototypical tumor 
rejection assay. CD91 KO mice and littermate controls were given intradermal immunizations 
with 1µg gp96 purified from the OVA-expressing EL.4 thymoma, E.G7, twice, one week apart. 
Cre- mice were protected from tumor challenge, while CD91 KO mice were not protected from 
tumor growth (Figure 4-8). Thus, CD91 KO mice appear to be incapable of priming immune 
responses capable of rejecting tumor cells following vaccination with extracellular HSPs.  
4.4 DISCUSSION 
In this chapter, we report that mice deficient in the receptor CD91 on CD11c+ cells display 
reduced immune protection against growing tumors, dependent on CD8+ T cells. In addition, 
mice were similarly susceptible to tumors expressing inhibitors of CD91 ligand binding. These 
reductions in anti-tumor immunity were due to the inability of APCs to cross-present HSP-
 
Figure 4-8. CD11cCD91 KO mice are not 
protected by gp96 vaccine.  
CD91-/- or CD91+/+ mice were immunized with 1 
µg E.G7 tumor-derived gp96 twice, one week 
apart, followed by E.G7 tumor challenge one week 
later. Tumor growth was monitored. 6-10 mice per 
group. n.s., not significant; * P<0.05; **P<0.01. 
Performed by RJB.  
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chaperoned antigens. To our knowledge, these findings are the first reports of a role for CD91 in 
antigen cross-priming in vivo.  
When antigen is abundant, acquisition of antigens by APCs for cross-presentation and 
cross-priming can occur through several mechanisms as in most infectious disease settings [170]. 
These mechanisms are less reliant on the source of antigen or the type of APC [171]. The 
majority of tumor rejection antigens, however, derive from novel mutations of self-proteins 
which are expected to be limited in quantity at the time initial anti-tumor responses are primed 
[172]. As previously demonstrated for transplantable tumors, immunity to additional challenge 
by syngeneic tumors is established within the first week of tumor growth, when intradermal 
tumors are barely visible [162]. A careful quantification and titration of the amount of antigen in 
tumors revealed there is ~5 orders of magnitude less available for cross-presentation as required 
if the antigen is transferred as a whole protein [166]. Clearly, a special mechanism is necessary 
for efficient transfer of antigens from tumor cells to cross-presenting cells, namely receptor-
targeting by chaperoning HSPs. Here we confirm that interaction of HSP-peptide complexes 
with CD91 provides this mechanism.  
Loss of CD91 on CD11c+ cells results in increased tumor burdens. However, not all 
immune responses were inhibited as CD91 KO mice were still capable of rejecting SVB6. At 
high antigenic loads, the requirement for CD91:HSP interaction may not hold (data not shown). 
There may also be a role for other APC that express CD91. Given the recent observation that 
CD169+ macrophages are bonafide professional APC in the setting of apoptotic-associated 
antigen in LNs [159], we expect a more robust phenotype when CD91 expression is eliminated 
in both macrophages and dendritic cells. Studies are currently underway to create mice with loss 
of CD91 in both CD11c+ and CD11b+ cells.  
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It was not surprising that only low amounts of gp96EGFP drain to LNs of tumor bearing 
mice given the low rate of spontaneous cell death at only 2 days after tumor inoculation. All 
detectable signal was lost with co-expression of RAP or knock-out of CD91 in CD11c+ cells. 
This decrease in EGFP signal suggests CD91 blockade inhibits transport of gp96 by a migratory 
subset in the tumor setting. This subset may be a minority of the cells identified in Aim 1, such 
as the CD8+ cells observed to be increased 48 hrs after vaccination.   
The effect of CD11c-specific CD91 loss on the ability to prime immune responses 
downstream of gp96 vaccine was striking given that no difference in the targeted subsets was 
observed in the draining LNs of CD91 KO mice in the vaccine setting in Aim 1 (Figure 3-13). 
We confirmed there is no intrinsic defect in presentation of peptides by CD91 KO mice by 
immunizing with OVA-8mer peptide, SIINFEKL, in Freund’s adjuvant. This peptide requires no 
further processing for presentation; we found that CD91 KO mice and Cre- controls generated 
comparable anti-SIINFEKL T cell responses (not shown). We are testing additional 
immunogenic models to verify there are no other disruptions in processing peptides or priming 
immune responses independent of the HSP:CD91 interaction.  
These studies show the important role for HSP:CD91 interaction in priming anti-tumor 
immune responses and suggest potential mechanisms of tumor evasion by enhancing expression 
of CD91 inhibitors. In addition to the CD11c-specific CD91 expressing cells analyzed here, 
more specific cell types involved in this immunity are under current investigation.  
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5.0  AIM 3: ELUCIDATION OF THE PATHWAYS FOR ANTIGEN-PROCESSING 
FOLLOWING HSP:CD91 INTERACTION  
5.1 PREFACE 
Some data from this chapter has been published in the Journal of Immunology [140], and is 
expanded on here. Those who performed the experiments detailed in this chapter are indicated by 
their initials in the figure legends (Michelle Messmer: MNM; Laura Kropp: LEK; Joshua 
Pasmowitz: JP).   
5.2 RATIONALE 
Antigen processing and presentation is classically depicted as occurring along two distinct, 
biologically separate pathways: 1) processing of endogenous peptides by proteasome followed 
by transport via TAP into the ER and loading onto MHC class I complexes, or 2) processing of 
exogenous peptides following endocytosis and fusion of the endosome with the lysosome, 
acidification, and loading onto MHC class II. As we now know, exceptions to these classical 
processing pathways exist, exemplified by the observation of “cross presentation” of exogenous 
derived peptides on MHC class I molecules. The modern complexities of the MHC class I and 
class II processing pathways have been reviewed elsewhere [173].  
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We are interested in understanding the pathway taken by HSP-chaperoned peptides since, 
once taken into the cell, HSPs can convey their conjugated peptides to either MHC class I 
[99,109,166] or class II [108,174,175]. The steps between endocytosis of HSP-peptide 
complexes and presentation of the peptide on the cell surface are still unclear. Internalization of 
gp96 occurs via clathrin coated vesicles [94], dependent on interaction with CD91 [98]. After 
endocytosis, antigens may follow a number of different paths for presentation onto MHC class I 
or class II [176-181]. A number of labs have shown localization of endocytosed HSPs in early 
endosomal compartments that may contain MHC class I for direct loading of HSP-chaperoned 
peptides [88,94,118,119,182-184], however, this does not answer how even extended length 
peptides may be efficiently processed for presentation. Additionally, differential requirements for 
the proteasome and TAP have been observed [107,119], as well as localization of HSPs to other 
cellular compartments [88,184,185], including the cytosol [185].  
The maturation state of APC can also have a major impact on the processing and 
presentation of antigens. When APC undergo maturation, they switch their primary directive 
from sampling the environment (constitutive endocytosis/phagocytosis) to professional 
presentation of antigens [186]. We were interested in understanding the effects of APC 
maturation on the expression of the HSP receptor CD91 and how this may alter the ability of 
APC to internalize HSPs and efficiently process and present HSP-chaperoned peptides.  
We show that bone marrow-derived dendritic cells (BMDC), which share a common 
phenotype with the cells observed in Aim 1 as targets for gp96 in vivo, are capable of processing 
HSP-chaperoned peptides or presentation by both MHC class I and MHC class II for stimulation 
of two distinct restricted T cell hybridomas. We observed internalization of gp96-peptide 
complexes, followed by dissociation of the two molecules concurrent with gp96 crossing into the 
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cytosol immediately prior to peptide translocation. Finally, we found that stimulation of BMDC 
by LPS up-regulates expression of CD91 in a time dependent manner.  
5.3 RESULTS 
5.3.1 Peptides chaperoned by HSPs are 
cross-presented by CD11b+CD11c+ cells 
Cross-presentation of HSP-chaperoned 
peptides after uptake by CD91 is necessary 
for priming effective immune responses 
[98,99]. To study the cross-presentation of 
peptides chaperoned by HSPs in detail, we 
adopted the use of bone marrow derived 
dendritic cells (BMDCs). These cells express 
a similar phenotype to the cells we identified 
as targets of gp96 following in vivo 
vaccination in Aim 1, including dual 
expression of CD11c and CD11b [161] as 
well as the HSP receptor CD91 [22]. 
Adopting this culture system gave us 
significantly more CD11b+CD11c+ cells than 
 
Figure 5-1. Re-presentation of gp96 chaperoned 
peptides by BMDC. 
(A) Cross presentation of HSP-chaperoned peptides by 
MHC I of CD11b+CD11c+ cells was tested by incubation 
of cells with gp96-HELOVA. Response by B3Z was 
measured as specific absorbance at 595nm. Controls 
include cells with HELOVA alone, OVA, ova 8mer 
peptide and PBS.  (B) Cross presentation of HSP-
chaperoned peptides by MHC II of CD11b+CD11c+ cells 
was tested by incubation of cells with gp96-HELOVA. 
Response by LC21 was measured by ELISA for IL-2. 
Controls include incubations of cells with HELOVA 
alone, HEL, HEL14 mer peptide and PBS.   Experiments 
are representative of 3 independent experiments.  Error 
bars are standard deviation of duplicates. Performed by 
LEK. 
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could be obtained from lymph nodes and reduces concerns about different maturation/activation 
states at baseline.  
We first confirmed that BMDCs were functionally competent in cross-presenting gp96-
chaperoned peptides on either MHC class I or MHC class II molecules. Gp96 was complexed to 
a 22-mer peptide (HELOVA) consisting of HEL 14-mer peptide presented by H-2IAd in tandem 
with the OVA8-mer peptide presented by H-2Kb, as described in detail in the Material & 
Methods section. BMDCs were generated from H-2b (C57BL/6) x H-2d (BALB/c) F1 mice and 
incubated in the presence of 10 μg of gp96-peptide complexes and T cell hybridomas specific for 
either OVA8/Kb (B3Z) or HEL14/IAd (LC21) for 20 hrs. HELOVA peptide chaperoned by gp96 
was processed into OVA and HEL epitopes which were presented by F1 BMDCs on their 
respective MHC molecules and subsequently detected by B3Z (Figure 5-1A) or LC21 (Figure 
5-1B) respectively. As a control, HELOVA peptide alone at a concentration similar to what was 
introduced to the assay in a complex with gp96, was poorly cross-presented. Similarly, as we 
have previously shown, whole protein (OVA or HEL) was poorly cross-presented by BMDC. 
Internalization of gp96 to endosomal compartments of APCs has previously been 
visualized [94,97], however to our knowledge no studies have shown trafficking of both HSP 
and chaperoned peptides within cells. To follow the association between HSP and peptide after 
endocytosis, we complexed gp96A488 to a biotinylated 20mer peptide (b-pep20). BMDCs were 
incubated with 10 μg of gp96A488-b-pep20 for the indicated times points and temperatures 
(Figure 5-2A-D). Cells were fixed, permeabilized and stained with streptavidin-Cy3 for detection 
of peptide and phalloidin for detection of actin filaments. Co-localization was quantified using 
IMARIS software to obtain Pearson’s coefficient of co-localized volume (Figure 5-2E-G). After 
5 minutes of incubation at 37°C most of the peptide localized to gp96, but by 15 minutes the two 
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molecules appeared dissociated (Figure 5-2A,B,E). At 15 minutes, peptide co-localized with 
actin suggesting translocation into the cytosol (Figure 5-2B,F). Surprisingly, gp96 was also 
found to co-localize with actin after only a 5 min incubation (Figure 5-2G). This suggests that, 
first, gp96 translocates to the cytosol independently of peptide and, second, gp96 dissociates 
from the peptide in the endosome prior to translocation.  
BMDCs incubated with gp96A488-b-pep20 were also stained with LAMP-1, a lysosomal 
marker (Figure 5-2H). Consistent with previous reports [152], gp96 did not localize with 
 
Figure 5-2. Transport of HSP-chaperoned peptides within CD11b+CD11c+ BMDCs. 
(A-D) gp96A488-b-pep20 was incubated with CD11b+CD11c+ cells on cover slips at 37oC (C-E) or 4oC (F), for the 
indicated time points and then stained with strepavidin-Cy3 for the peptide (red) and phalloidin (blue). Gp96A488 
appears as a green signal.  (E-G) Images were analyzed using IMARIS and co-localization of gp96A488 with peptide 
(E), peptide with the phalloidin (F), or gp96 with the phalloidin (G) was quantified.  Experiments are representative 
images from numerous independent experiments. Error bars are standard deviation of multiple ROIs. Data are 
represented as mean +/- SEM. (H) gp96A488 was incubated with CD11b+CD11c+ cells on cover slips for 15 mins 
after which cells were fixed and stained for LAMP-1 (blue) and phalloidin (red). Co-localization of gp96A488 with 
LAMP-1 was quantified by IMARIS.  Performed by MNM and JP.  
 62 
lysosomes (Pearson’s coefficient of colocalized volume =0.0065), suggesting that the rapid 
translocation of gp96 into the cytosol (Figure 5-2G) prevents it from being targeted to and 
degraded in lysosomes.  
5.3.2 Activated APC up-regulate expression of CD91 
We were interested in determining whether activation of BMDC alters the expression of the HSP 
receptor CD91, thereby altering the potential for HSP:CD91 interaction and internalization. First, 
we confirmed the expression of CD91 on BMDC generated from either WT (Figure 5-3A) or 
CD91 KO mice (Figure 5-3D). Day 7 BMDC from both mice show mixed CD11c+ and CD11c- 
expression. WT BMDC have detectable CD91 expression on all cells, though at variable levels 
of intensity. As described in the Material & Methods section, CD91 KO mice are specific for 
CD91 depletion only on CD11c+ cells. As expected, CD11c- cells from these mice retain CD91 
expression (yellow arrow) while CD11c+ cells were largely deficient in CD91 (white arrow). 
Rare CD11c+ cells did show low levels of CD91 expression.  
Next, we investigated the effects of LPS treatment on the expression of CD91 by these 
BMDC. LPS was selected for its well-studied effects on BMDC activation. After 4 hrs 
stimulation with LPS, both WT and CD91 KO BMDC adopted a more uniform expression 
pattern of CD11c by almost all cells. WT BMDC have a more dendritic appearance and show 
uniform expression of CD91 throughout the cell, which does not appear to co-localize to CD11c 
expression. CD91 KO BMDC also have a dendritic morphology and retain KO of CD91 on 
many of the CD11c+ cells, however, with 4 hrs stimulation in LPS, a number of CD11c+ cells 
now co-express CD91 as well. After 24 hours stimulation with LPS, WT and CD91 KO BMDC  
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Figure 5-3. Increased expression of CD91 with LPS treatment. 
BMDC were generated from Cre- littermates (A-C) or CD91 KO mice (D-F) as described in Materials & Methods. 
BMDC were treated with LPS on day 6 (24 hrs (C,F)) or day 7 (4 hrs (B,E)) or left untreated (0 hrs (A,D)). Cells 
were stained with anti-CD91 EPR3724 (red), anti-CD11c (green), and Hoechst nuclear dye (blue). Performed by 
MNM.  
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round up, adopting an appearance typically associated with migration. While WT BMDC appear 
to have less CD91 by microscopy, the KO BMDC have a number of CD91 bright cells.  
5.4 DISCUSSION 
There is a current focus on determining how material in endosomal compartments translocates to 
the cytosol for processing [142,185,187]. Previous studies have shown that peptides chaperoned 
by HSPs are processed by proteasomes and require TAP transport prior to presentation on MHC 
class I [22]. Following endocytosis, dissociation of peptide from gp96 occurred rapidly. This 
dissociation could reflect changes in pH or activity of compartment-specific enzymes [188]. 
Alternatively, a recently identified endosome specific ‘unfolding’ mechanism could cause the 
gp96 to relinquish the chaperoned peptide [187]. This ‘unfolding’ mechanism allows for 
stretches of polypeptides to be extruded to the cytosol. Short sequences can bypass this 
mechanism. Surprisingly, but consistent with this ‘unfolding’ mechanism, gp96 was observed to 
translocate to the cytosol rapidly and earlier than the peptide. This is also consistent with our 
observation that endocytosed gp96 is excluded from lysosomes. We expect that gp96 will be 
degraded in the cytosol [152]. In addition, the delay in peptide translocation to the cytosol may 
explain how some of these HSP-chaperoned peptides are presented by MHC class II [114]. Thus, 
peptide-containing vesicles may fuse with MHC class II loading compartments before peptide 
can be translocated to the cytosol. This concerted processing event and timed-translocation could 
explain how gp96-chaperoned peptides are presented on MHC class I or MHC class II by the 
same APC. We also observed the persistence of peptide within the cytosol of cells which could 
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be the result of re-association of peptide with endogenous HSPs within the APC 
[36,152,187,189].  
 Surface expression of CD91 is required for interaction with and internalization of 
extracellular HSPs. In our studies of BMDC, we have confirmed expression of CD91 by these 
cells, but have yet to clarify the localization of this receptor within cellular organelles. We are 
interested in determining whether CD91 localization is regulated in a similar manner to the 
expression of MHC class II, with maturation resulting in a redistribution from cellular stores to 
the cell surface [190,191]. We have also observed that expression of CD91 varies over time after 
maturation; this is especially clear when comparing receptor expression for the CD11c-specific 
CD91 KO BMDC. Given that day 6 BMDC are a relatively immature population [161], the 
observed co-expression of CD91 and CD11c on these cells at 4 hrs and 24 hrs may be due to 
novel CD11c expression on CD11c- precursor cells which have undergone additional 
differentiation with LPS stimulation [192], and may retain residual CD91 at the observed time 
points. Our observation that CD91 expression ultimately decreases upon LPS stimulation is 
supported by a number of previous reports showing down regulation of CD91 following LPS 
treatment [193,194], potentially mediated by increased expression of SREBP1 [195]. 
Interestingly, when BMDC were treated with fluorescently tagged gp96, only “immature cells” 
(CD11c+CD86neg) were able to bind the HSP while CD11c+CD86hi cells showed no binding, 
suggesting loss of CD91 expression during normal maturation, without the need for stimulation 
by LPS [71]. Given that gp96 binding delivers a maturation signal through CD91 as well, we are 
interested in employing mutated CD91 receptors to determine if loss of this maturation signal 
will alter retention of gp96 and its chaperoned peptide [196]. Additional requirements for CD91 
expression in the development of APCs is also under investigation.  
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 These studies elucidate the cellular processes downstream of HSP:CD91 interaction. 
HSPs are ancient, stress-responsive molecules, and their ability to interact with CD91 on 
immune cells to generate peptide-specific immune responses is evolutionarily conserved [100]. 
By understanding the mechanism of HSP-chaperoned antigen presentation we gain insight into 
the evolutionary development of these complicated pathways.  
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6.0  SUMMARY & FUTURE DIRECTIONS 
Heat shock proteins may be found in the extracellular environment due to membrane damage, 
active secretion, or by administration of HSPs as a vaccine. These HSPs are capable of 
generating highly efficient and specific immune responses via their interaction with the receptor 
CD91. The characterization of the cellular players and processes involved in generating these 
responses is important to understanding retention of this responsive pathway throughout 
evolution as well as highlighting potential means of altering immune responses via use of HSPs 
in various disease settings.  
 All of these studies rely on our ability to detect gp96 using a fluorescent molecule, either 
Alexa Fluor 488 for our exogenous gp96 administration or EGFP for our studies of endogenous 
gp96 release. While these markers are a powerful tool, they have some drawbacks. Namely, the 
accuracy of tracking of these proteins is dependent on the specificity of the label, limit of non-
specific targeting due to label-protein interactions, and the stability of the tag. These issues will 
be discussed in the following paragraphs. 
A488 labels free primary amines, such that any contaminating proteins in our gp96 preps 
may also be labeled. Thus, we may mistake off-target labeled protein binding for gp96 binding. 
However, as shown previously [65], and as demonstrated by Coomassie staining and immuno-
blotting of our purified proteins (Figure 3-1A), our gp96 preparations are highly purified. 
Contaminants are unlikely to account for the majority of the signal observed. Ideally, co-staining 
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with an anti-gp96 antibody might clarify that the major subsets observed are specifically binding 
gp96 rather than a non-specific contaminant. This approach, however, is complicated by the high 
expression of endogenous gp96 by most cells, which would produce a high level of background 
staining. Genetic labeling of gp96 with EGFP reduces the question of specificity since our 
construct only allows EGFP expression at the C-terminus of gp96 and is unlikely to have EGFP 
cleaved from the fusion protein and still remain fluorescent. Purified gp96EGFP could be used to 
validate the cellular subsets identified with A488 conjugated protein. Alternatively, uptake of 
gp96A488 could be competitively inhibited with unlabeled gp96 to show specificity, especially in 
our ex vivo experiments.  
Another major concern associated with tracking labeled proteins is altered protein-protein 
interactions due to addition of the tag. Steric inhibition of normal protein interactions due to 
bulky tags can disrupt ligand receptor binding. The molecular weight of the Alexa fluor 488 
carboxylic acid, tetrafluorophenyl ester used to label gp96 is ~885 Da, equivalent to 
approximately eight amino acids. Multiple A488 molecules label each molecule of gp96, and are 
expected to be distributed along the gp96 structure. As mentioned in Aim 1, previously published 
reports using gp96 similarly labeled with FITC (molecular weight of 389 Da) showed no 
disruption in the ability of gp96 to bind its receptor and deliver peptide for cross-presentation 
[96]. Thus, labeling with A488 would not be expected to block receptor binding, and our data 
shows that peptides associated with gp96A488 are delivered for cross-presentation. 
Comparatively, EGFP is ~32.7 kDa, or 37 times larger than A488. Although EGFP is 
significantly larger, it is distant from the N-terminus of gp96. The N-terminus has been shown to 
be sufficient for binding peptides and interacting with CD91 [45]. Thus, any steric effects on 
receptor binding from this bulky C-terminal tag are also expected to be limited. Studies of the 
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ability of this fusion protein to chaperone peptides for cross-presentation are warranted to 
confirm that the gp96 folding and function are not compromised in vivo.  
Some labeling dyes non-specifically interact with substrates other than the protein to 
which they are conjugated. Chemically, A488 carries a negative charge and is hydrophilic, 
limiting the amount it non-specifically interacts with other substrates [197]. Receptors for the 
molecules A488 or EGFP may exist; to confirm the targeted cells are not a by-product of 
receptor interaction with the labels rather than gp96, unconjugated A488 as a control vaccine and 
control tumors expressing KDEL tagged EGFP could be used.  
Detection of gp96 is also dependent on the stability of the fluorescent molecules. Unlike 
earlier dyes, A488 is highly photostable and pH insensitive over the range of 4-10 [198]. 
However, the natural amino acids Trp, Tyr, His, and Met are capable of quenching this molecule 
[199]. This quenching is due to photo-induced electron transfer, such that if the labeled gp96 is 
in a compartment containing high concentrations of these amino acids or is closely associated 
with proteins containing these amino acids at the time of analysis, the signal may be below the 
limit of detection. EGFP, a relatively complex protein tag, is highly dependent on its structural 
stability for fluorescence. Assays for the stability of this protein showed that it is relatively stable 
following treatment with the protein denaturant guanidinium chloride, in elevated temperatures, 
as well as exposure to various detergents and proteases [200,201]. The half-life of EGFP in 
mammalian cells is ~26 hrs, but this can be modulated by fusion with other proteins’ proteolytic 
groups [202]. Studies into the stability of the gp96EGFP fusion protein’s half-life in the 
extracellular environment are warranted to determine the length of time gp96EGFP may be 
detectable after release from tumor cells. Both the A488 and EGFP fluorescence spectra overlap 
with the fluorescence spectra of many endogenous molecules, raising the limits of detection. 
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Alternative fluorescent proteins based on the structure of EGFP have been developed with 
enhanced stability and fluorescence in the red spectrum to avoid issues with high background.  
Questions on our ability to detect this protein become extremely important when looking 
at the internalization of gp96 and its subsequent processing. As we and others have shown, 
internalized gp96 fails to localize to lysosomal compartments. The dyes used in this study are 
relatively insensitive to this pH change, allowing us to be confident in this observation. 
However, it is unclear if A488 tagged gp96 would lose its fluorescence immediately upon gp96 
degradation or if we may continue to visualize gp96 peptide fragments after the protein may be 
cleaved. Thus, we need to confirm our observation of gp96 transport into the cytosol using 
additional methods. Potentially, we may be able to co-stain for gp96 with a fluorescent antibody 
and look for overlap. Alternately, we could conduct a pulse-chase experiment and isolate the 
various cellular compartments for analysis by Western blot to confirm if the A488 labeled bands 
continue to correspond to full length gp96 or to degradation bands with increasing time within 
the various compartments. 
It is important to remember when elucidating these pathways that the various cell subsets 
may also utilize alternate antigen processing routes [160,203,204], and this can also depend on 
the maturation status of the APC.  The processing pathways for the HSPs should be examined for 
a number of cell types, and compared between immature or matured populations.   
Assuming that gp96A488 behaves as normally purified autologous gpp96 vaccines, Aim 1 
demonstrates that upon vaccination with gp96, this protein is predominately endocytosed by 
CD91 expressing CD11c+CD11b+CD4+ cells in the subcapsular region of the LNs. These cells 
rapidly and preferentially take up protein both in vivo and in vitro. Given that these cells would 
contain the bulk of antigen for presentation, this suggests that they must play a major role in 
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defining immune responses to gp96. However, since our experiments with the adoptive transfer 
of immunogenic cells relied on bulk A488+ cells rather than subdividing based on APC 
phenotype, an absolute requirement for this subset in gp96-mediated immune responses has not 
been established. Unexpectedly, there were no alterations in gp96A488
+ subsets observed in CD91 
KO mice.  This may be due to the relatively low expression of CD11c on the CD11b+ subset, 
such that selective deletion of CD91 only on CD11c+ cells may have been incomplete for this 
subset. We would expect to see a greater effect on gp96 endocytosis in a dual CD11b/CD11c 
specific CD91 KO, as proposed in the discussion in Aim 2. However, the population identified is 
naturally highly endocytic and a CD91-independent A488 labeled protein, mouse serum 
albumin, showed no difference in cellular targets (data not shown). Thus, there may be features 
of these cells that lead them to uptake HSPs even when CD91 is lacking, such as increased rates 
of phagocytosis, pinocytosis, etc. Interestingly, in Aim 2 we show generally that immune 
responses to tumor, and specifically to gp96 vaccine, have a strong dependence on the expression 
of CD91 on CD11c expressing cells. Though we have already confirmed that these CD91 KO 
mice are capable of presenting a peptide for priming T cell responses independent of processing, 
we have not confirmed that these cells are capable of processing antigen following uptake that is 
not dependent on the receptor CD91.  
It is important to clarify that the endocytosis of gp96 may not be the critical feature of 
gp96-mediated immunity disrupted in our CD11c-specific CD91 KO mice. Deficiency in gp96 
signaling through CD91 on CD11c+ cells may reduce effective priming. As we have shown that 
interaction of gp96 with CD91 elicits a variety of cytokines, it may be that this cell-specific 
deletion abrogates a critical cytokine response from the CD11c+ cells. We may also have reduced 
the ability of these cells to mature in response to gp96 signaling. Although we do not show that 
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these cells are the major targets for endocytosis of gp96, they may receive antigen from gp96+ 
cells via antigen transfer but still be dependent on an extracellular maturation signal. Indeed, we 
observed that transfer of gp96ErkA488
- subsets from gp96ERK complex treated mice were also 
capable of inducing protection against CMS5 tumor, with growth curves comparable to those 
observed for the gp96ErkA488
+ group shown in Aim 1 Figure 3-9, pg 34. It is not clear if these cells 
received antigen from one of the gp96+ subsets, or if they may more rapidly process internalized 
antigen, degrading the fluorescent signal.  
We are currently investigating mice deficient in defined APC subsets, such as the Batf3 
KO mice that have lost CD8α+ and CD103+ DCs [205], for their ability to respond to HSP-based 
vaccines. Although our uptake data did not implicate the CD8α+ or CD103+ subsets as major 
cellular populations that take up gp96, their role in cross presenting antigens in other systems has 
been well established [205-207]. It may be that only a very small number of these cells are 
indeed responsible for generating the observed immune responses. Our studies focused on the 
cells that quantitatively took up the majority of gp96 but did not fully assess the qualitative 
outcome of gp96 endocytosis, namely the processing of gp96-chaperoned peptide for 
presentation. Thus, we cannot rule out that deficiency in Batf3 may also abrogate gp96-mediated 
immune responses.  
APC in the homeostatic LN are considered to be in an immature state [208]. Since our 
data on CD91 expression shown in Aim 1 was derived from naïve animals, it will be important to 
clarify if there are any changes in CD91 expression in the LNs of vaccinated mice. CD91 may 
increase in expression after APC stimulation, or matured APC may recruit additional CD91 
expressing cells. The nature of the maturation stimulus may also differentially impact CD91 
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expression [196]. The effects of this regulation on antigen processing and presentation deserve 
more investigation.  
The role of dose on immune responses to gp96 is an especially intriguing feature of these 
studies as we have observed differential effects in cell subsets targeted in vivo versus in vitro. 
The immunogenic dose of gp96 in vivo clearly preferentially targets cells with an APC 
phenotype (expressing CD11b or CD11c), and our ex vivo data on LN subsets confirmed these 
cells are the preferred endocytic cells as well. Surprisingly, increasing the dose of gp96 in vivo 
targeted an entirely different population that were negative for CD11c and CD11b, despite these 
cells showing no endocytic capacity ex vivo. The nature of the gp96 responsive CD11b-CD11c- 
cells in vivo has yet to be clarified; this population in the high dose vaccinated LN may represent 
a newly recruited or expanded population not present in the isolated naïve LNs. This would 
explain the discrepancy in endocytic capacity, however this must also be an extremely rapid 
recruitment, as these differences were observed very early, just 8 hrs, after vaccination. An 
alternative explanation could be that the LN structure may allow transfer of high dose gp96 to 
the CD11b-CD11c- via a mechanism that may be disrupted ex vivo, such as close cell to cell 
contact. Further surface marker characterization on the CD11b-CD11c- population should be 
conducted to identify this population and the potential mechanism behind this observed 
discrepancy.  
Our tumor model expressing fluorescent gp96 is an excellent tool for studying the 
complicated immunological processes at play in the tumor microenvironment. The role for heat 
shock proteins in tumor cells is controversial; while HSPs are capable of stimulating immune 
responses, patients whose tumors over-express HSPs often have a worse prognosis. There are 
multiple cell types present in the tumor microenvironment that may express CD91 and respond 
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to HSPs, including tumor associated macrophages, plasmacytoid dendritic cells, and myeloid 
derived suppressor cells. These cells may be recruited and activated by the HSPs released in the 
growing tumor environment and respond by suppressing anti-tumor effector cells, contributing to 
increased disease burden. Studies of gp96EGFP expressing tumor cells co-cultured with these cell 
types may shed light on the mechanistic pathways for immune suppression by HSP release. Also, 
as discussed earlier, the expression of CD91 by T cell populations remains controversial; while 
we have been unable to confirm CD91 on murine T cells, we have not ruled out a potential direct 
effect of HSPs on stimulating T regulatory cells. Additionally, as we have already shown [24], 
cytokines downstream of HSP signaling on APCs, when combined with the appropriate tumor 
microenvironment, can alter the phenotype of responding effector cells. Thus, we are very 
interested in following up on the cytokine production in and around cells expressing or 
endocytosing gp96EGFP in the tumor.   
As introduced, HSPs have already been tested in clinical trials as cancer therapeutics. 
Despite promising results in murine studies, only a small number of patients showed partial or 
complete responses to autologous gp96 therapy. This may be due to immunosuppressive effects 
of the tumor microenvironment, or it may be due to differences in immune cell targeting of the 
gp96 vaccine. As shown in mice, dosing can play a major role in determining the outcome of the 
immune responses generated by HSPs. The optimal dose for humans has yet to be determined. 
Trials to date have used 20-50 ug of protein per dose, which is similar to the amounts of protein 
used to vaccinate mice. This dose was calculated based on the amount of antigen theorized as 
necessary to generate immune responses and with a concern to avoid giving a “high,” 
immunosuppressive dose. Other than clinical response, the effectiveness of the vaccine has been 
difficult to monitor. The studies on the effects of dose on the targeted cell populations in the 
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lymph node in Aim 1 suggest an approach for tracking autologous vaccine within a patient using 
draining lymph node biopsies. The ability to confirm appropriate dosing by analyzing the cellular 
subsets that have taken up the protein could assist in tailoring vaccine dose to enhance 
effectiveness.  
All of these studies were performed with a prototypic HSP, gp96. However, as our lab 
has already shown, other HSPs give rise to different immune outcomes following CD91 
engagement. It will be important to clarify if the findings discussed here are universally 
applicable or if other HSPs target different cell populations or differentially regulate CD91 
expression. Given the distinctive patterns of CD91 phosphorylation after treatment with the 
different HSPs [24], we would predict altered cytokine responses as well as altered rates of 
endocytosis and the downstream signaling that results in maturation.  
Overall, HSPs are clearly capable of inducing immune responses through their 
interactions with the receptor, CD91. Aim 1 demonstrated the major cells targeted by HSP 
vaccine express CD11b and high levels of CD91. Aim 2 demonstrated the dependence on HSPs 
and CD91 for generation of anti-tumor immune responses. Aim 3 showed the intracellular 
pathways critical to processing HSP and peptide for efficient presentation. These three aims lay 
the foundation for continuing research on the basic mechanisms of HSP-mediated immune 
responses that will clarify the early stages of immune system development. The pathways our 
immune cells developed in order to respond to stressful or dangerous conditions are clearly 
rooted in their ability to detect HSPs. A better understanding of these mechanisms will guide us 
toward the situations in which utilizing HSPs may provide the greatest benefits.  
 76 
7.0  MATERIALS & METHODS  
Those who performed the experiments or generating novel methods in this chapter are indicated 
by their initials in the figure legends (Michelle Messmer: MNM; Sudesh Pawaria: SP; Laura 
Kropp: LEK; Joshua Pasmowitz: JP).   
7.1 MICE  
Female C57BL/6, BALB/c, C57BL/6 x BALB/c “F1 mice,” C.129S7(B6)-Rag1tm1Mom/J 
(rag1-/- BALB/c), and B6(Cg)-Rag2tm1.1Cgn/J (rag2-/- C57BL/6), C57BL/6-
Tg(TcraTcrb)1100Mjb/J (OT-1), 
B6.SJL-PtprcaPepb/BoyJ (CD45.1) 
were purchased from The Jackson 
Laboratory (Bar Harbor, ME) and 
housed in the animal facility at the 
University of Pittsburgh. 
Experimental mice were used 
between the ages of six to eight 
weeks. All mice were used according 
 
Figure 7-1. Mating scheme for CD11c specific CD91 KO mice. 
Development of this breeding scheme by SP.  
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to IACUC protocols approved by the University of Pittsburgh and in accordance with the 
National Institutes of Health (Bethesda, MD) guidelines.  
7.1.1 Generation of CD11c specific CD91 knockout mice 
B6;129S7-Lrp1tm2Her/J (CD91flox/+) mice originally generated by [209] were purchased from 
Jackson Laboratory (Bar Harbor, ME) and mated to homozygosity (CD91flox/flox). CD11c specific 
CD91 knockout mice were generated by crossing B6.Cg-Tg(Itgax-cre)1-1Reiz/J (CD11c-Cre) 
mice with CD91flox/flox mice. Members of the F1 generation were then backcrossed with the 
homozygous CD91flox/flox parent and confirmed CD91flox/flox CD11cCre+ offspring were mated for 
all subsequent generations (Figure 7-1).  
7.2 CELLS AND REAGENTS  
7.2.1 Cell lines  
Lung carcinoma D122, methylcholanthrene-induced fibrosarcoma CMS5, Simian Virus 40 
(SV40)-induced SVB6, and macrophage-like RAW264.7 were obtained from American Type 
Culture Collection (ATCC, Manassas, VA) and cultured as recommended in Dulbecco’s 
modified Eagle’s medium supplemented with 1% sodium pyruvate, 1% L-glutamine, 1% non-
essential amino acids, 1% penicillin and streptomycin, 0.1% 2-mercaptoethanol and 10% fetal 
bovine serum (FBS) (complete DMEM, GIBCO). RAW264.7 cells previously transfected using 
a Kb plasmid (RAW264.7 Kb) as described [210] were also maintained in complete DMEM.  
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RAP or control vector-transfected CMS5 tumor cells were cultured in complete DMEM 
media plus blasticidin (3g/mL, Invitrogen). Double transfected tumor cells (gp96EGFP+RAP, or 
gp96EGFP+control vector) were cultured in complete DMEM media plus blasticidin (3g/mL, 
Invitrogen) and geneticin (0.7g/L, GIBCO).  
Retroviral immortalized DC line D2SC/1 (a generous gift from Dr. P. Ricciardi-
Castagnoli, Cellular and Molecular Pharmacology Center, Milan, Italy, [211]) were maintained 
in complete DMEM with heat inactivated FBS. Prior to experiments, D2SC/1 cells were treated 
with 12 ng/ml of recombinant INFγ (invitrogen, Carlsbad, CA) for 48 hours to increase 
expression of surface MHC.  
T cell hybridomas, B3Z (provided by Dr. Nilabh Shastri, UC Berkeley) and LC21 
(provided by Dr. Jean-Charles Guery at the Institut National de la Sante et de la Recherche 
Medicale, France) as well as the T cell lymphoma EL4 (ATCC) were grown in RPMI Medium 
1640 supplemented with 5% FBS, 1% nonessential amino acids, 1% penicillin and streptomycin, 
1% pyruvate, 1% glutamine, 1ml/L of β-mercaptoethanol. 
All cell cultures were stored in a liquid nitrogen cell bank at the University of Pittsburgh 
in 20% DMSO/80% FBS freezing media until thawing for culture at 37˚C in a humidified 
atmosphere containing 5% CO2. 
7.2.2 Generation of bone-marrow-derived dendritic cells 
Bone marrow derived dendritic cells were obtained by culturing bone marrow cells from F1 
mice, CD91 KO mice, or Cre- controls for 6 days in DMEM containing 10% heat-inactivated 
fetal calf serum (50°C for 30 minutes) and supplemented with GM-CSF on days 0 and 3 as 
previously described [161].  
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7.2.3 Purification of gp96 and labeling with Alexafluor 488 
For all experiments, gp96 was purified as previously described [212]. In detail, batches of 30-50 
livers from C57Bl/6 or BALB/c mice, either freshly harvested or previously frozen at -20°C, 
were blended into 30 mL phosphate buffered saline supplemented with additional 1.75g NaCl 
per liter, 300 µL Halt Protease Inhibitor Cocktail, EDTA-free (Thermo Scientific, Rockford, IL), 
one tablet cOmplete protease inhibitor, EDTA-free (Roche Diagnostics, Indianopolis, IN), and 
30 µL 0.2M Phenylmethylsulfonyl fluoride (PMSF). Blended livers were pooled and the volume 
of PBS was increased to ~3 mL per liver before samples were centrifuged at 5,700 x G for 10 
min. Supernatant was then subjected to ultra-centrifugation at 100,000 x G for 90 min. 
Supernatants were then brought to 50% Ammonium Sulfate by slow addition of the salt while 
stirring in an ice bath.  This solution was then centrifuged at 14,000 x G for 30 min. Supernatants 
were then brought from 50% to 80% Ammonium Sulfate as before, followed by an additional 
14,000 x G centrifugation for 30 min. The 80% salt pellet is resuspended in 10 mL per liver of 
‘Con A PBS’ (prepared with 2L distilled H2O, 1 packet PBS powder (Sigma Aldrich, St. Louis, 
MO), 12.26 g NaCl, 4 mL 1M CaCl, 4 mL 1M MgCl2, and 10 mL 0.2 M PMSF) prior to 
application to Concanavalin A-agarose column (GE Healthcare, Chalfont St. Giles, United 
Kingdom). Glycoproteins were eluted by 10% methyl-α-D-mannose pyranoside Con A PBS. 
Eluate was then applied to sepharose gel columns (also purchased from GE Healthcare) to 
exchange into DEAE buffer (prepared by combining 2L 0.005M monobasic sodium phosphate 
solution with 2L 0.005M dibasic sodium phosphate solution to a pH of 7.2, followed by addition 
of NaCl to 0.3 M).  Protein was then loaded onto equilibrated DEAE Sephacel columns (GE 
Healthcare) and eluted with 0.7 M NaCl DEAE buffer. Fractions were concentrated using a 
10,000 MWCO spin column (Ultracel 10K, Amicon Ultra, Millipore, Billerica, MA). Protein 
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concentration was determined by Bradford analysis (Bradford reagent purchased from Biorad, 
Hercules, CA). Absorbance at 595 nm was measured using a Biorad Model 680 microplate 
reader. Protein purity was analyzed by SDS-PAGE using a 10% Bis-acrylamide gel (Biorad). 
Apparently homogenous preparations of gp96 were labeled with Alexafluor A488 
(Molecular Probes, Invitrogen, Grand Island, NY) using a labeling kit optimized for labeling of 
immunoglobulin molecules according to the manufacturers recommendation. In detail, 1M 
bicarbonate buffer was added to approximately 2 mg/mL purified gp96 to a final concentration 
of 0.1M bicarbonate before transferring the protein to a vial of the reactive Alexa Fluor 488 dye 
and mixing for 1 hour at room temperature. Free dye was removed by size exclusion 
chromatography using the provided column components. Protein concentration was measured by 
Bradford analysis. Labeled gp96 is referred to as gp96A488. Protein was analyzed by SDS-PAGE 
and immunoblotting with anti-gp96 (Enzo Life Sciences, Inc. Farmingdale, NY) and anti-A488 
(Invitrogen, Grand Island, NY) antibodies.  
7.2.4 HSP:Peptide Complexes  
To generate specific anti-CMS5 responses, the H-2Kd restricted immunodominant epitope from 
ERK2 (ERK2136-144, QYIHSANVL)[151] was conjugated in a 100:1 peptide to gp96A488 molar 
ratio as previously described [28], termed gp96A488-ERK. To measure cross-presentation of a 
dual epitope peptide, HELOVA was constructed of the HEL I-Ad restricted immunodominant 
epitope (HEL12-25, MKRHGLDNYRGYSL) in tandem with the OVA H-2K
b restricted 
immunodominant epitope (OVA257-264, SIINFEKL). Gp96 was complexed to HELOVA as 
described above to obtain gp96HELOVA. To track processing of peptides within BMDCs, an 
extended 20 amino acid OVA peptide containing the above epitope was biotinylated before 
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conjugating with gp96A488 to obtain 
gp96A488-b-pep20. All peptides were 
synthesized at Genemed Synthesis, Inc. 
(San Antonio, TX). Free peptide was 
removed from all conjugation reactions by 
size exclusion membranes.  
We confirmed that immune 
responses to HSP:peptide complexes are 
due to peptides bound by HSPs and not free 
peptide by washing prepared HSP 
conjugates three times in 4mls PBS on a 10,000 MW cut off centricon. Flowthrough was saved, 
condensed by air drying, pulsed onto D2SC/1 cells which were cultured overnight with LC21 
cells. Activation of LC21 was measured by ELISA for IL-2. As shown in Figure 7-2, even the 
flowthrough from wash 1 did not elicit a measurable response, while 10μg/ml of gp96HELOVA 
conjugate was able to elicit a response comparable to direct addition of 1uM of the specific MHC 
class II epitope, HEL14. 
7.2.5 Antibodies 
Dilutions and specific use for the antibodies below are included in the Experimental Methods 
section. Anti-CD8 depleting antibody was purified from culture supernatant of TIB210 
hybridoma (ATCC). 
Table 7-1. Antibodies for Flow Cytometry 
Name Clone Isotype Manufacturer Conjugate 
Anti-CD91 11H4 Mouse IgG1 Hybridoma from ATCC, Unconjugated 
 
Figure 7-2.  Free HELOVA peptide does not stimulate 
LC21.  
100 µL flowthrough from preparing HSP:peptide 
complexes, 1  µL Hel14, or 10 µg gp96HELOVA complex 
was pulsed onto D2SC/1 cells in co-culture with LC21 for 
24 hrs. Production of IL-2 was measured by ELISA. 
Performed by MNM.  
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purified by Sudesh Pawaria 
Anti-CD91 5A6 Mouse IgG2b abcam Unconjugated 
Anti-CD8a 53-6.7 Rat IgG2a BD Pharmingen Pacific Blue, APC 
Anti-CD4 RM4-5 Rat IgG2a BD Pharmingen PerCP-Cy5.5 
Anti-CD11c HL3 Arm. Hamster IgG1 BD Pharmingen PE, APC 
Anti-CD103 M290 Rat IgG2a BD Pharmingen FITC, PE, BV421 
Anti-CD205 205yekta Rat IgG2a eBioscience APC 
Anti-CD207 eBioL31 Rat IgG2a eBioscience PE 
Anti-CD11b M1/70 Rat IgG2b BD Pharmingen PE-Cy7 
Anti-F4/80 BM8 Rat IgG2a eBioscience eFluor 450 
Anti-CD45 30-F11 Rat IgG2b Invitrogen APC 
Anti-Gr1.1 RB6-8C5 Rat IgG2b BD Pharmingen PerCP-Cy5.5, Alexa 
Fluor 700 
Anti-I-A/I-E M5/114.15.2 Rat IgG2b BD Pharmingen PE 
Anti-CD107a 1D4B Rat IgG2a eBioscience Unconjugated 
Anti-CD3 Complex 17A2 Rat IgG2b BD Pharmingen PE-Cy5 
Anti-CD3e 145-2C11 Arm. Hamster IgG1 BD Pharmingen APC 
Anti-CD19 1D3 Rat IgG2a BD Pharmingen APC 
Anti-NK1.1 PK136 Mouse IgG2a BD Pharmingen PE-Cy7 
 
Table 7-2. Antibodies for Microscopy 
Name Clone Isotype Manufacturer Conjugate 
Anti-CD8 53-6.7 Rat IgG2a BD Pharmingen Biotin 
Anti-CD4 RM4-5 Rat IgG2a BD Pharmingen Biotin 
Anti-CD11c HL3 Arm. Hamster IgG1 BD Pharmingen  Unconjugated 
Anti-CD103 M290 Rat IgG2a BD Pharmingen Biotin 
Anti-CD207 eBioL31 Rat IgG2a eBioscience Biotin 
Anti-CD11b M1/70 Rat IgG2b BD Pharmingen Unconjugated 
Anti-CD19 1D3 Rat IgG2a BD Pharmingen Biotin 
Anti-I-A[b] AF6-120.1 Mouse (BALB/c) IgG2a BD Pharmingen Unconjugated 
Anti-PDI 34/PDI Mouse IgG1 BD Transduction Laboratories Unconjugated 
Anti-CD91 EPR3724 Rabbit IgG abcam Unconjugated 
 
Table 7-3. Antibodies for Western Blot 
Name Clone Isotype Manufacturer Conjugate 
Anti-CD91 11H4 Mouse IgG1 Hybridoma from ATCC, purified by 
Sudesh Pawaria 
Unconjugated 
Anti-CD91 EPR3724 Rabbit IgG abcam Unconjugated 
Anti-grp94 Polyclonal Rabbit IgG Enzo Unconjugated 
Anti-Alexa Fluor 488 Polyclonal Rabbit IgG Molecular Probes Unconjugated 
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7.2.6 Additional reagents  
Ovalbumin, hen egg lysosome, complete Freund's adjuvant, incomplete Freund's adjuvant, and 
mitomycin-C were purchased from Sigma (St. Louis, MO). Ovalbumin was rendered free of 
endotoxin by detoxi-Gel columns (Thermo Scientific).  
7.3 EXPERIMENTAL METHODS 
7.3.1 Tracking vaccine gp96 in vivo  
Mice received ventral intradermal immunizations with gp96A488 in 100 μl saline. Doses of 
gp96A488 are indicated in each experiment. In some experiments, lymph nodes were isolated after 
indicated incubation periods, mechanically disrupted and passed through a 20μm strainer.  
7.3.2 Flow cytometry  
Cells were blocked with anti-CD16/CD32 antibody (BD Pharmingen, San Diego, CA) for 10 
minutes before addition of fluorescent-tagged surface antibodies for 20 minutes. Where 
indicated, cells were fixed in 4% paraformaldehyde and stained with anti-CD91 extracellular β-
chain clone 5A6 (abcam) followed by allophycocyanin or FITC conjugated rat anti-mouse IgG2b 
(BD Pharmingen) according to the recommended protocol. Major subtyping was performed 
using the following panel of antibodies: CD11c allophycocyanin, CD11b PECy7, CD8 Pacific 
Blue, and CD4 PerCPCy5.5 (BD Pharmingen). Additional markers were included as indicated 
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(Figure 3-4). Data was collected on a Becton Dickinson LSR2 (Franklin Lakes,NJ) using 
Cellquest software and analyzed using FlowJo version 7 (Treestar, Inc., Ashland, OR).  
7.3.3 Microscopy  
Lymph node and tumor tissues were fixed in 2% paraformaldehyde and then stored in 30% 
sucrose solution at 4°C overnight. Tissues were frozen by submersion in 2-methyl-butane cooled 
by liquid nitrogen and stored long term at -80°C. Sections (8-10 μm) were prepared in Neg50 
freezing media on a HM505 Microm Cyrostat, and adhered to Fisherbrand Superfrost Plus 
Precleaned Microscope Slides (Fisher Scientific). Slides were stored at -20°C until staining using 
a protocol developed by the Center for Biologic Imaging (CBI, University of Pittsburgh). 
Primary antibodies included biotin conjugated CD11b, CD4, CD8, CD207, CD103 and purified 
Armenian Hamster anti-CD11c (BD Pharmingen & eBioscience, San Diego, CA). Secondary 
antibodies were Cy5 conjugated goat-anti-Hamster IgG and DyLight 549 conjugated 
Streptavidin (Jackson ImmunoResearch, West Grove, PA).  
To visualize intracellular trafficking of gp96-peptide complexes, day 6 BMDCs were 
grown overnight on coverslips. Gp96A488-b-pep20 was pulsed onto BMDCs for indicated times 
at 37oC or 4oC. Cells were washed, fixed in paraformaldehyde, permeabilized and stained using a 
protocol developed by the Center for Biologic Imaging (CBI, University of Pittsburgh). Cells 
were stained with Cy3 conjugated strepavidin (Jackson ImmunoResearch), phalloidin and/or 
LAMP-1 specific antibody (Invitrogen).  
Imaging of CD91 on BMDC was accomplished by growing 3x105 day 6 WT or CD91 
KO BMDC on coverslips overnight, with or without LPS. Cells were again processed using the 
protocol from CBI and stained with anti-CD91 β-chain clone EPR3724 and anti-CD11c followed  
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by Cy3 conjugated anti-rabbit and Cy5 conjugated anti-Armenian hamster secondary antibodies 
(Jackson ImmunoResearch).  
All images were captured using an Olympus 1000 inverted confocal microscope with 60x 
objective and Fluoview v. 2.1 acquisition software (Melville, NY). Imaris v. 7.2.1 (Bitplane, 
Zürich, Switzerland) and Photoshop v. 7.0 (Adobe, San Jose, CA) were used for analysis and to 
 
Figure 7-3. Microscopic analysis of gp96A488 in draining LN. 
LNs were harvested 8 hr post 10ug gp96A488 injection and fixed in PFA, incubated in sucrose, frozen, and serially 
sectioned. Sections were then stained with Cy5 (CD11c; blue) and Cy3 (separately, either CD4, CD8, CD11b, 
CD103 or CD207; red). Images were taken at 20x magnification by confocal microscopy (column 1). Regions of 
interest were selected for colocalization analysis (yellow boxes, column 1; expanded in column 2). Individual 
fluorescence channels are shown in Columns 3-5. Column 6 shows a colocalization channel generated using Imaris 
software (white; indicates regions of red and green overlap). This colocalization is quantified in Figure 3. Performed 
by MNM.  
 86 
prepare the images for publication. Examples 
of images processed for co-localization are 
shown in Figure 7-3.  
7.3.4 Adoptive transfer of gp96A488+ cells  
Lymph node cells were harvested from 
BALB/c mice 6 hours after vaccination with 
gp96A488 or gp96A488-ERK and sorted by 
FACSAria (BD Bioscience, San Jose CA) 
based on A488 positivity. Sorted cells were 
washed in saline, and suspended at a 
concentration of 1x105 per 100 μL for transfer 
to naïve BALB/c mice via intravenous, retro-
orbital injection. Mice were rested for one 
week and then challenged with 1x106 CMS5 
cells. Tumor growth was monitored starting at 
day 4 and 2-3 days thereafter. For some 
experiments, cells were gamma irradiated with 
7,000 rad prior to adoptive transfer.  
7.3.5 Cross-presentation assay 
 
Figure 7-4. Titration of HSP:peptide complexes in 
the representation assay. 
(A) Representation assay for MHC class I presentation 
of OVA. APCs used were RAW264.7 Kb, with B3Z T-
cells. Activation was measured by absorption at 595 
nm following cleavage of the CPRG substrate by 
βgalactosidase generated under the IL-2 promoter.To 
the right of the graph is a standard curve generated 
using the change in absorption in response to increasing 
amounts of OVA8 peptide.  (B) Representation assay 
for MHC class II presentation of HEL. APCs used were 
D2SC1, with LC21 T-cells. Activation was measured 
by ELISA for IL-2. To the right of the graph is a 
standard curve generated using the change in IL-2 
concentration in response to increasing amounts of 
HEL14 peptide.  Performed by MNM.  
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In separate duplicate wells, BMDCs were cultured in 200 l of complete media containing 20 g 
of gp96-HELOVA, HEL or OVA, or 0.05 g HELOVA, 0.03 g HEL14 or 0.17 g OVA8. T 
cell hybridomas B3Z specific for OVA8/Kb [213] or LC21 specific for HEL14/IAd [214] were 
added at BMDC to T cell hybridoma ratio of 1:1 with 1x105 cells of each. B3Z has been 
transfected with a gene for β-galactosidase under the IL-2 promoter, allowing for determination 
of activation by addition of substrate chlorophenolred-ß-D-galactopyranoside (CPRG) that 
produces a color change upon cleavage by β-galactosidase with absorbance measurable at 595 
 
Figure 7-5. gp96EGFP construct schematic. 
Schema for gp96EGFP (C-terminal fusion protein) construction by sequential PCR and subcloning. Gp96 cDNA was 
amplified from murine RNA using N-terminal primer, gp96NT2, and C-terminal primer, gp96CTNde1. The codons 
for ER retention sequence, KDEL, and the stop codon were replaced with an NdeI restriction cut site [1]. EGFP was 
prepared via 2-step PCR. First, EGFP cDNA was amplified from a commercial vector (Invitrogen) using 
complementary commercial N-terminal primer and C-terminal primer, GFPCTKDEL, with an overhang including 
KDEL and a stop codon [2]. EGFP was then reamplified using N-terminal primer, GFPNTNde1, with an NdeI 
restriction site overhang and C-terminal primer, GFPCTNot1, complementary to the previous primer’s extansion, 
and including a NotI restriction site overhang [3]. Final products of the PCR reactions are shown at [4]. The gp96 
PCR product was inserted into the pEF6/V5-His-TOPO vector and orientation was confirmed by restriction enzyme 
digestion and sequencing analysis [5] (Figure 7-6). The final EGFP construct was ligated into the gp96 containing 
vector [6] and the final product [7] was fully sequenced to confirm the sequences were in frame and that no 
mutations occurred during the construct assembly process. Scheme generated by MNM, with suggestions by SP.  
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nm [213].  LC21 activation is measured directly by the amount of IL-2 production as determined 
by ELISA.  
7.3.6 Plasmid gp96EGFP construction and transfection 
The gp96EGFP (C-terminal fusion protein) was generated by sequential PCR and subcloning. 
Schema for this experimental design is shown in Figure 7-5. The gp96 cDNA was amplified 
from murine RNA using an N-terminal primer upstream of the gp96 start codon (gp96NT2) and 
a C-terminal primer with complementarity starting at nucleotide 2483 (gp96CTNde1). The 
codons for KDEL, an ER retention signal sequence, and the stop codon were replaced with an 
NdeI restriction cut site. EGFP was prepared via 2-step PCR due to biochemical/physical 
 
Figure 7-6. Vector map and restriction cut sites. 
The gp96 PCR product was subcloned into the pEF6/V5-His-TOPO vector. Vectors containing the gp96 PCR insert 
were then analyzed for correct orientation by digestion with ECO RI and XbaI (Figure 7-7C). EGFP was then 
inserted into the vector-gp96 construct by digestion with NdeI and NotI followed by ligation, with only a single 
orientation possible for successful EGFP insertion (Figure 7-7D,E). Sequencing was used to confirm the final 
gp96EGFP containing vector was free of point mutations and in the predicted orientation. Vector map from 
Invitrogen.   
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restrictions on the number of 
bases that can be added by a 
single primer. First, EGFP 
cDNA was amplified from a 
commercial vector (Invitrogen) 
using a complementary, 
commercial N-terminal primer 
and a complementary C-terminal primer with an overhang for the KDEL and stop codons 
(GFPCTKDEL). EGFP was then reamplified using an N-terminal primer with an NdeI restriction 
site overhang (GFPNTNde1) and a C-terminal primer complementary
 to the C-terminus with KDEL and stop codons and with a NotI restriction site overhang 
(GFPCTNot1). Final PCR products for gp96 and EGFP are in Figure 7-7A. The PCR construct 
Table 7-4. Primers for gp96EGFP construct. 
1. gp96NT2: 30 bases + 3 bps  for Kozak sequence 
        5’   GGG ATG AGG GTC CTG TGG GTG TTG GGC CTC TGC    3’  
2. gp96CTNde1: 20 bases not including stop codon +NdeI site + 3 bps  
        5’   CCC CAT ATG CTC TGT AGA TTC CTT TTC TGT TTC CTC   3’ 
3. GFPNTNde1: 20 bases + NdeI site + 3 bps  
        5’   GGG CAT ATG ATG GTG AGC AAG GGC GAG GA    3’  
4. GFPCTKDEL: (1st PCR)19 bases + KDEL + Stop 
        5’    TTA CAA TTC ATC CTT TCT AGA TCC GGT GGA TCC C 3’ 
5. GFPCTNot1- (2nd PCR) (GFP+KDEL+Stop) + Not I site + 3 bps  
        5’   GGG GCG GCC GCT TAC AAT TCA TCC TTT CTA GAT CCG   3’ 
 
Figure 7-7. Stepwise results for gp96EGFP construct process. 
Results of each step in the gp96EGFP construction process. (A) gp96 and EGFP were PCR amplified from mouse 
cDNA or EGFP containing vector, respectively, by step-wise PCR using the primers in Table 7-4 according to the 
scheme in Figure 7-5, steps 1-4. The gp96 PCR product was inserted into the pEF6/V5-His-TOPO vector (Figure 
7-6) and cloned into E.coli. Plasmids were purified (B) and restriction enzyme-digested (C) to determine correct 
orientation (ex. plasmid 4). (D) vector-gp96 and EGFP PCR products were both digested with NotI and NdeI to 
linearize the vector and provide the sticky ends on EGFP for ligation. Ligated product was then cloned into E.coli, 
plasmids were purified, and then digested with EcoRI with cut sites in gp96 and EGFP but no sites within the vector. 
(E) Plasmids containing EGFP and gp96 have a 2.3 Kbp insert, while plasmids lacking EGFP are just linearized (ex. 
plasmid 9). Performed by MNM.  
 90 
was inserted into the pEF6/V5-His-TOPO vector and orientation was confirmed by restriction 
enzyme digestion and sequencing analysis (Figure 7-6, Figure 7-7B,C). The final EGFP 
construct was ligated into the gp96 containing vector and the final product (Figure 7-7E) was 
fully sequenced to confirm the sequences were in frame and that no mutations occurred during 
assembly of this construct.  
7.3.7 Analysis of HSPs draining from tumor 
For HSP transfer experiments in vivo, 5x106 CMS5 cells co-transfected with RAP and gp96EGFP, 
or CMS5 co-transfected with control vector and gp96EGFP, were injected in one footpad of wild 
type BALB/c or CD91 KO mice. Two days later, the draining and contra lateral (non-draining) 
popliteal lymph nodes were harvested. EGFP signal in CD45+ cells in the lymph nodes were 
compared as described in the text (Aim 2, pg. 53).  
7.3.8 CD91 independent T cell priming 
CD91 KO mice and Cre- littermates were immunized subcutaneously with 20g OVA 8 peptide 
emulsified in Freund's adjuvant at an interval of one week. One week after the last vaccination, 
5x106 splenocytes were harvested from OVA 8 peptide immunized mice and cultured ex vivo for 
5 days in the presence of OVA 8 peptide. Specific T cell responses were monitored by IL-2 
ELISA. 
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7.3.9 Tumor growth assays in CD91 KO mice 
8x105 D122 or 1x106 SVB6 tumor cells were injected intradermally in CD91 KO or control 
mice, with or without CD8 depletion. Tumor growth was measured on two axes thereafter. CD8 
T cells were depleted with anti-CD8 antibody one day before tumor challenge as previously 
described [215].  
7.4 STATISTICAL ANALYSIS 
Differences between the means of experimental groups were analyzed using the two tailed 
Student’s t-test.  Differences were considered significant when p ≤ 0.05. Error bars were 
calculated as standard error of the mean (SEM). 
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